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ABSTRACT 
 
Brain metastasis is a common cause of mortality in cancer patients.  Approximately 
20-30% of breast cancer patients acquire brain metastasis, yet potential therapeutic 
targets remain largely unknown. The type I insulin-like growth factor receptor (IGF-
IR) is known to play a role in the progression of breast cancer and is currently being 
investigated in the clinical setting for various types of cancer. The present study 
demonstrates that the IGF-IR signaling axis is constitutively active in brain-seeking 
sublines of breast cancer cells, driving an increase in in vitro metastatic properties.  
We demonstrate that IGF-IR signaling is activated in an autocrine manner as a 
result of IGFBP3 overexpression in brain-seeking cells.  Transient and stable 
knockdown of IGF-IR results in a downregulation of IGF-IR downstream signaling 
through phospho-AKT, as well as decreased in vitro migration and invasion of MDA-
MB-231Br brain-seeking cells.  Using an in vivo experimental brain metastasis 
model, we show that IGF-IR ablation attenuates the establishment of brain 
metastases and prolongs survival. Finally, we demonstrate that the malignancy of 
brain-seeking cells is attenuated by pharmacological inhibition with 
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picropodophyllin, an IGF-IR-specific tyrosine kinase inhibitor. Together, our data 
suggest that the IGF-IR is an important mediator of brain metastasis and its ablation 
delays the onset of brain metastases in our model system. 
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CHAPTER 1 
 
INTRODUCTION
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1.1 Metastatic Brain Tumors (MBTs) of Breast Cancer 
Brain metastases are the most frequent type of malignant brain tumors, and they 
commonly originate from lung, breast, melanoma, renal, and colon cancers 
(Barnholtz-Sloan et al., 2004; Eichler et al., 2011; Weil, Palmieri, Bronder, Stark, & 
Steeg, 2005). Approximately 10-16% of breast cancer patients develop brain 
metastases, and this continues to be a major cause of mortality in women 
(Barnholtz-Sloan et al., 2004; Cheng & Hung, 2007; Saunus, Momeny, Simpson, 
Lakhani, & Da Silva, 2011; Weil et al., 2005).  The mean survival of patients with 
brain metastases ranges from 3-18 months, with a one-year survival rate of 20% 
(Andrews et al., 2004; Cheng & Hung, 2007; Sperduto et al., 2010).  One recent 
retrospective study found that the presence of leptomeningeal disease (LMD) or 
triple-negative/Her2 status correlated with an even poorer than overall median 
survival of 3.1 months (Quigley, Fukui, Chew, Bhatia, & Karlovits, 2012).  A 
retrospective study found that survival time is longer in patients who had a single 
metastatic lesion at diagnosis that was resected by surgery or gamma knife surgery 
(14.9 months), followed by patients who received whole brain radiotherapy alone 
(5.4 months), as compared to the patients who received no treatment (2.1 months) 
(S. S. Lee et al., 2008).  The incidence of brain metastases is thought to be on the 
rise as patients are living longer due to the success of current therapies at 
controlling systemic disease while increasing the likelihood of circulating tumor cells 
to infiltrate the blood brain barrier (Cheng & Hung, 2007; Steeg, Camphausen, & 
Smith, 2011).  Brain metastases are even more common in patients with Her2-
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positive breast cancer who received treatment with Trastuzumab, which is very 
effective at controlling Her2-positive systemic disease but has poor effectiveness in 
the brain due to presence of the blood-brain barrier (N. U. Lin & Winer, 2007).  
Unfortunately, the increase in the proportion of patients presenting with brain 
metastases has not been met with a corresponding increase in available 
treatments, and there remains an urgent need for effective therapies to prevent and 
treat this condition. 
 
1.2 Organ specificity of breast cancer metastasis 
Stephen Paget’s 1889 “seed and soil” hypothesis predicted that cancer cells, or 
“seeds” crosstalk with certain organ microenvironments, or “soil”, during the process 
of metastasis (Paget, 1989).  Another theory of cancer metastasis is the anatomical 
or mechanical model, which posits that tumor cells metastasize to the first organ 
they encounter in the circulation, as in the case of colon cancer liver metastasis 
(Langley & Fidler, 2011).  The extent to which each of the models most closely 
describes the process of metastasis remains unclear, but the consensus is that both 
anatomical and microenvironmental factors are at play.  Like several other cancer 
types, breast cancer preferentially metastasizes to certain organs, including the 
bone, lungs and liver.  Figure 1 shows a schematic of a metastasizing breast cancer 
cell and the various barriers it must overcome in order to establish successful 
metastases.  The brain is typically the last organ to acquire metastatic lesions, due 
to the initial protection provided by the blood-brain-barrier. 
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Molecular mechanisms underlying organ-specificity are continuously being 
uncovered, but there is still a long way to go in our understanding.  A major 
determinant of breast cancer cells’ ability to colonize in a new niche depends on the 
ability of the tumor cells to arrest, adhere to and penetrate the different organ 
barriers, and subsequent survival and proliferation of the cells in the metastatic 
niche.  Figure 1 depicts a metastatic breast cancer cell in the circulation, and the 
various layers that must be overcome in order for the cell to invade the bone, lung 
and brain (Nguyen, Bos, & Massague, 2009). 
In bone metastasis, chemokines such as SDF-1, osteonectin and osteopontin, 
among others, are known to promote breast cancer cell homing to the bone 
(Langley & Fidler, 2011).  Expression level of CXCR4, the SDF-1 receptor in breast 
cancer cells was found to predict bone relapse in a recent clinical trial of patients 
with breast cancer (Sacanna et al., 2011).  Furthermore, a gene signature 
comprising mainly of cell surface and secreted proteins was found to determine the 
bone-specific metastasis of 231 breast cancer cells (Kang et al., 2003).  Two of the 
genes, interleukin-11 and CTGF, corresponded to osteolytic factors that are further 
enhanced by the prometastatic cytokine TGF beta, which is commonly secreted in 
bone (Buijs, Stayrook, & Guise, 2011). 
Brain metastasis is a relatively new field of study, and it has recently come into 
focus due to its increasing incidence, limited treatment options and dismal survival 
rates.  A 2009 study by Bos. et al. identified several genes that mediate 
extravasation of breast cancer cells through the blood-brain-barrier.  
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Cyclooxygenase COX2, HB-EGF (an EGFR ligand) and ST6GALNAC5, a 
sialyltransferase collectively accounted for the brain-metastatic properties of breast 
cancer cell lines (Bos et al., 2009).  Another study by Palmieri et al. found Her2 
overexpression increases brain metastasis of 231 breast cancer cells in a mouse 
model (Palmieri et al., 2007).  In a subsequent study, the same group discovered 
that PEDF, a secreted cytokine, is downregulated in brain metastases, and its 
restoration inhibits the outgrowth of large brain metastases, while simultaneously 
offering neuroprotection to neuronal cells (Fitzgerald et al., 2012).  Furthermore, a 
recent study by Su et. al. found that TAp63-/- mice can develop mammary 
carcinomas that spontaneously metastasize to the lung, liver and brain (Su et al., 
2010).  Another study showed that CXCR4 and its ligand SDF-1 alpha promoted 
migration the transendothelial migration of breast cancer cells by increasing 
permeability of monolayers of brain microvascular endothelial cells (B. C. Lee, Lee, 
Avraham, & Avraham, 2004).  Most recently, a study by Okuda et al showed 
microRNA-7 is downregulated in brain metastases of breast cancer, resulting in 
upregulation of KLF4, which endows metastatic breast cancer cells with stem-like 
qualities and brain-specificity (Okuda et al., 2013). 
Despite these advances in the study of brain metastasis in breast cancer, there is 
much work to be done to complete our understanding of the disease. 
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Figure 1 
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Figure 1. Potential barriers to metastasis of breast cancer to different sites. 
"Breast cancer cells entering the circulation can infiltrate a distant organ if they 
carry the necessary functions for extravasation. The fenestrated structure of bone 
marrow sinusoid capillaries is more permissive to cancer cell infiltration than the 
contiguous structure of lung capillary walls. Brain capillaries are more difficult to 
penetrate, owing to the unique nature of the blood-brain-barrier. Infiltration through 
these barriers selects for tumor cells that express the necessary extravasation 
functions. These functions can be provided by genes for which expression in 
primary tumors independently provides a selective growth advantage (such as 
vascular remodeling) or by genes for which expression in primary tumors provides 
no benefit but is a consequence of tumor microenvironment signals.” 
Reprinted with permission from Macmillan Publishers LTD: [Nature Reviews 
Cancer] (Nguyen et al., 2009), copyright 2009. 	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1.3 Role of the organ microenvironment in metastasis 
It is well established that the tumor microenvironment actively participates in the 
metastatic process, through the interaction with the Extracellular Matrix (ECM) and 
recruitment of a variety of cells including tumor-associated fibroblasts, immune cells 
and bone-marrow derived cells (Joyce & Pollard, 2009).  A recent study published 
by Luga et. al. showed that breast cancer associated fibroblasts secrete exosomes 
that activate the Wnt-PCP (planar cell polarity) pathway which induces cancer cell 
protrusions and motility, leading to metastasis (Luga et al., 2012).  The tumor 
microenvironment, thus, is an important factor in determining whether metastatic 
foci will establish successfully. 
1.4 EMT and tumor cell plasticity in metastasis 
EMT, or epithelial-mesenchymal-transition, is the process by which cells switch their 
morphology and biochemical properties from epithelial to mesenchymal type (Kalluri 
& Weinberg, 2009).  This process involves loss of expression of epithelial markers 
such as E-cadherin, adherens junction proteins and catenins, concomitant with a 
gain of expression in mesenchymal markers such as vimentin and fibronectin 
(Thiery, 2002).  EMT allows cancer cells to dissociate from the tumor and acquire 
the ability for invasion and metastasis (Kalluri & Weinberg, 2009).  However, the 
role of EMT in metastasis is considered “controversial”, due to a scarcity of in vivo 
evidence of the EMT process.  The controversy is fueled by studies that found 
metastatic tumors tend to have epithelial-like properties, not mesenchymal 
properties as suggested by the EMT theory (Ledford, 2011).  However, many argue 
that EMT must be a reversible process, termed MET, necessary for metastatic cells 
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to survive and proliferate in the target organ.  A recent paper by Tsai and 
colleagues in the journal Cancer Cell showed that inducible expression of the 
transcription factor Twist1 is sufficient to promote the EMT transition in cancer cells, 
and shutting off this protein in the target organ where cells have metastasized 
results in a reversion of EMT, or MET, and allows cells to proliferate successfully in 
the metastatic site (Tsai, Donaher, Murphy, Chau, & Yang, 2012).  In addition, Tsai 
et al. argue that a “partial EMT” may be sufficient for metastasis in some cases, a 
feature that facilitates the MET process in the distant organ and which has been 
reported in a recent study of bladder cancer metastasis (Tran et al., 2013).  
Furthermore, it has been shown that repression of MET-inducing factors (Ocana et 
al., 2012) and a reversal of EMT is a hallmark of successful metastasis (Chaffer et 
al., 2006).  Interestingly, a partial MET phenotype was reported by Chao et al. in 
prostate cancer and breast cancer metastases, including brain metastases, 
characterized by re-expression of E-cadherins with mostly conserved expression of 
mesenchymal markers (Y. Chao, Wu, Acquafondata, Dhir, & Wells, 2012).  The 
authors postulated that a partial MET not only facilitates metastasis in the first target 
distant site, but also facilitates the subsequent round of EMT that enables 
metastasis from metastasis.  Taken together, these recent studies point to a 
metastasis model whereby tumor cells possess a degree of plasticity that is molded 
by the primary tumor and the metastatic site’s stromal microenvironment, rather 
than a fixed genetic signature that dictates a sequence of metastatic steps. 
However, even with mounting evidence in favor of EMT/MET theory, there is a 
different school of thought that advocates for genetic selection, or a kind of 
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Darwinian adaptation as the basis for metastasis.  This theory posits that metastasis 
is the end result of a series of genetic mutations that occur in response to 
environmental pressures.  Rather than one theory prevailing over the other, it is 
likely that both mechanisms are at play in metastasis formation.  Scheel et al., for 
example, propose that genetic selection is likely responsible for the early stages of 
metastasis leading up to the pre-invasive stage, while it is unlikely that genetic 
evolution is responsible for all of the biochemical and morphological changes that 
allow cells to dissociate from the solid tumor.  This is supported by observations that 
EMT typically takes place in the outer edges of “epithelial islands” within solid 
tumors (Scheel, Onder, Karnoub, & Weinberg, 2007); in other words, EMT happens 
primarily in those cells that are in direct contact with the host microenvironment, not 
in the entire tumor as would be expected in a genetic adaptation model.  Still, other 
cases exist that support a clonal selection model in which particular genetic profiles 
give rise to metastasis, such as evidenced in medulloblastoma metastases that 
have nearly identical genetic profiles to each other, but different from their primary 
tumor of origin (Wu et al., 2012).  Therefore, it is important to keep in mind both of 
these theories when evaluating the role of IGF-IR in brain metastasis of breast 
cancer in our model system. 
1.5 Blood-Brain Barrier 
The blood-brain barrier (BBB) is the layer that separates the brain microvessels’ 
capillary lumen from the brain parenchyma, and it plays an important role in both 
initially blocking tumor cell invasion and protection of the tumor cells once they have 
begun the process of invasion (Wilhelm, Molnar, Fazakas, Hasko, & Krizbai, 2013).  
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The BBB is composed of endothelial cells, a basal membrane, pericytes and 
astrocytes(Cheng & Hung, 2007; Wilhelm et al., 2013).  The BBB endothelial cells 
are connected by tight junctions and adherens junctions, which are composed of 
transmembrane proteins such as occludin, claudins, immunoglobulin-like molecules 
also known as junctional adhesion molecules, and others that have not been well 
characterized(Cheng & Hung, 2007; Wilhelm et al., 2013). 
1.6 Therapies for brain metastatic breast cancer 
Therapeutic approaches for the treatment of brain metastasis are limited.  In cases 
where brain metastases are diffuse, whole-brain radiotherapy (WBRT) is a standard 
therapy, but mainly provides a palliative solution, since tumors inevitably become 
resistant to radiation and recur (Padovani, Muracciole, & Regis, 2012).  One recent 
study identified the Hepatocyte growth factor (HGF) – c-Met pathway as 
overexpressed in breast cancer lines that were irradiated.  By combination of 
radiotherapy and c-Met inhibitors, they were able to harness this resistance 
pathway and synergistic effects in a mouse model, which may be a future direction 
for this line of treatment (Yang et al., 2013). 
Stereotactic radiosurgery (SRS), or gamma-knife radiosurgery, is used in cases with 
3 or less metastatic lesions.  Survival rates of patients treated by gamma-knife vary 
by subtype of the primary tumor, with HR+/Her2+ (luminal Her2) subtypes showing 
the longest survival and HR-/Her2- (basal type) with the lowest survival (Vern-Gross 
et al., 2012).  However, whether survival times are dependent on gamma-knife 
surgery itself is unknown.  A study of WBRT in combination with SRS showed 
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improved local control of disease, although overall survival remained the same 
(Tsao et al., 2012).  However, another study found that omission of WBRT with SRS 
led to progression of brain metastases (Dyer et al., 2012).  Discrepancies between 
the conclusions of these and many other studies highlight the complexity of the 
disease and the need for a better understanding of the underlying mechanisms that 
mediate response to the different available therapies. 
Despite the dearth of therapies for brain metastasis, some new approaches are 
beginning to show promise in the clinic.  In patients with Her2 positive metastatic 
breast cancer, Trastuzumab is the standard of care therapy.  When administered 
after the diagnosis of brain-metastatic disease, Trastuzumab extends overall 
survival, presumably due to control of systemic disease and relatively easier access 
to the brain in patients with a leaky blood-brain barrier (Mehta, Brufsky, & Sampson, 
2012).  In patients with an intact BBB, however, the drug’s molecular weight is too 
large to gain access into the brain parenchyma.  A recent Phase II clinical trial 
tested the efficacy of systemic treatment with lapatinib in combination with 
capecitabine as a first-line therapy for Her2-positive metastatic breast cancers 
previously untreated for brain metastases.  In this setting, the drug combination 
achieved 65% response consisting of at least 50% volumetric reduction of brain 
metastases, and all patients in the study achieved at least a partial response 
(Bachelot et al., 2013).  Interestingly, patients treated with the combination of 
lapatinib plus capecitabine received a 7 month increase in survival compared to 
patients who were treated with trastuzumab-based therapy (Kaplan et al., 2013). 
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Since it is believed that the efficacy of brain metastasis therapies are mostly limited 
by the presence of the blood-brain-barrier, new techniques are under development 
that focus on overcoming this obstacle.  One such new technique is called 
ultrasound-mediated blood-brain-barrier disruption, which permeabilizes the 
BBB/BTB using focused ultrasound bursts and microbubbles in the circulation.  
When combined with trastuzumab treatment, this technique was shown to 
significantly extend the survival of rat model of brain metastasis of BT474 breast 
cancer cells, compared to controls treated with trastuzumab alone (Park, Zhang, 
Vykhodtseva, & McDannold, 2012). 
1.7 The type-I Insulin-like growth factor signaling axis 
Figure 2 shows the key components of the IGF-I Receptor signaling axis discussed 
in the sections that follow. 
1.7.I IGF-I Receptor 
The type I insulin-like growth factor receptor (IGF-IR) is known to promote 
metastasis in several cancers, including those of the colon, pancreas, prostate, and 
breast (Chitnis, Yuen, Protheroe, Pollak, & Macaulay, 2008; Lopez & Hanahan, 
2002; Sachdev, Zhang, Matise, Gaillard-Kelly, & Yee, 2010). IGF-IR is composed of 
an extracellular α ligand-binding subunit and an intracellular β subunit responsible 
for signal transduction.  IGF-IR shares 84% homology with the intracellular tyrosine 
kinase domain of the Insulin Receptor (IR) (Fujita-Yamaguchi et al., 1986), and the 
homology is even higher in the ATP-binding site, at 95%.  It is therefore not 
surprising that IGF-IR receptors have been found to heterodimerize with IR and 
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successfully transduce IGF-1-dependent downstream signals (Takata & Kobayashi, 
1994).   
IGF-IR is activated upon binding the IGF-I ligand, although IGF-II ligand, which 
shares 62% amino acid sequence homology with IGF-I, can also bind and activate 
the receptor with a two to fifteen-fold lower affinity (Fernandez & Torres-Aleman, 
2012; Vashisth & Abrams, 2010; Yu & Rohan, 2000). Upon ligand binding, IGF-IR 
becomes autophosphorylated at Tyr 1131, 1135, and 1136 in the β subunit and 
subsequently recruits a host of proteins, including IRS-2, that activate signaling via 
PI3K/AKT and Ras/Raf/MAPK pathways to promote cell motility and pro-metastatic 
behavior in breast cancer cells (Chitnis et al., 2008; Jackson, Zhang, Yoneda, & 
Yee, 2001; Kato, Faria, Stannard, Roberts, & LeRoith, 1994).  It is common for 
breast tumor tissues to express high amounts of IGF-IR, although amplification at 
the DNA level has been found in some cases as well (Adelaide et al., 2007).  
1.7.II IGF-I and IGF-II ligands 
In models of breast cancer bone metastasis, IGF-I ligand promotes motility of bone-
metastatic cells through IGF-IR activation (Yoneda, Williams, Hiraga, Niewolna, & 
Nishimura, 2001), and bone-derived IGF-1 can activate the process of bone 
metastases in breast cancer in a paracrine manner (Hiraga et al., 2012). Inhibition 
of astrocyte-derived IGF-1 ligand was shown to reduce in vitro growth and adhesion 
of a brain metastatic variant of MDA-MB-435 breast cancer cells (Sierra et al., 
1997). 
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In breast cancer patients, phosphorylated IGF-IR associates with poor survival, and 
a recent study further showed that phosphorylation of IGF-IR at Tyr 1135/1136 is 
correlated with brain metastases of breast and lung cancers (Improta et al., 2011; 
Law et al., 2008). However, the biological significance of IGF-IR activation in brain 
metastases of breast cancer has not been addressed to date. 
1.7.II.A IGFBP3 
The regulation of IGF-IR signaling is complex and not yet fully understood; however, 
it is well established that the IGF-IR signaling axis can be dysregulated by altered 
expression of the IGF ligands and IGF-binding proteins. The insulin-like growth 
factor binding protein-3 (IGFBP3) is the major binding protein and regulator of IGF-1 
ligand bioavailability and has been reported to inhibit as well as potentiate the 
activity of IGF-IR signaling in different cancers (Firth & Baxter, 2002; Martin & 
Baxter, 2011; Schedlich & Graham, 2002). In the least malignant breast cancer cell 
lines, IGFBP3 plays an inhibitory role as a tumor suppressor, and this function is 
reversed in highly malignant breast cancer cells which express higher levels of 
IGFBP3 (Schedlich & Graham, 2002).  IGFBP3 also promotes migration in breast 
cancer cells (O'Han, Baxter, & Schedlich, 2009). In melanoma metastasis, IGFBP3 
is overexpressed in metastatic tissues and is associated with malignant progression 
(Xi et al., 2006). IGFBP3 was also shown to stimulate IGF-IR phosphorylation 
indirectly through activation of sphingosine kinase 1 (SphK1) and EGFR 
transactivation (Martin & Baxter, 2011). Adding yet another layer of complexity is 
the finding that IGFBP3 expression itself can be regulated by IGF-1 ligand through 
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PI3K/AKT signaling in mammary epithelial cells, suggesting that the IGF-IR axis is 
self-regulated in an autocrine manner (Sivaprasad et al., 2004). 
1.7.III Insulin receptor substrate (IRS) proteins 
Insulin Receptor substrate proteins act as signaling intermediates between cell 
surface receptors, such as Insulin Receptor and Insulin-like growth factor receptor, 
and downstream signaling molecules such as PI3K and MAPK pathways.  They do 
not possess kinase activity, but instead act as scaffolds upon which other signaling 
molecules dock to form signaling complexes (Mardilovich, Pankratz, & Shaw, 2009).  
The IRS protein family consists of several isoforms: IRS-1 was the first described as 
a phosphoprotein that became phosphorylated in response to insulin stimulation, 
IRS-2 was the second discovered, believed to be homologous to IRS-1, and IRS-4 
which is only expressed in the brain, thymus, liver and kidney (Shaw, 2011).   
The two most significant IRS isoforms in normal physiology are IRS-1 and IRS-2, 
and they perform essential complementary roles in the regulation of glucose 
metabolism (Taniguchi, Ueki, & Kahn, 2005).  Knockdown of IRS-1 in livers of 
normal mice resulted in accumulation of gluconeogenic enzymes and increased 
blood sugar levels, whereas IRS-2 knockdown resulted in upregulation of lipogenic 
enzymes and accumulation of hepatic lipid (Taniguchi et al., 2005).  The general 
consensus about the roles of IRS proteins in cancer is that IRS-1 and IRS-4 
associate with tumor growth and cell proliferation, while IRS-2 promotes invasion 
and motility (Mardilovich et al., 2009).  In breast cancer metastasis specifically, IRS-
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1 appears to be a metastasis suppressor while IRS-2 promotes the metastatic 
process (Gibson, Ma, & Shaw, 2007). 
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Figure 2 
 
domain, and that the insulin receptor A (IR-A) isoform,
in particular, is capable of binding IGF-2 with high affin-
ity and mediating mitogenic signaling and survival (9).
In addition, IGF-1R is capable of forming heterodimers
with insulin receptor that seem to mediate similar signal-
ing events to IGF-1R homodimeric receptors (10).
Several lines of evidence have established a role for the
IGF-1R pathway as an important target for cancer therapy.
A seminal finding was the observation that expression of
IGF-1R is required for neoplastic transformation by a num-
ber of cellular and viral oncogenes, including SV40 large
T antigen, HRAS, and epidermal growth factor receptor
(EGFR), suggesting an obligatory role between expression
of this receptor and the acquisition of a transformed pheno-
type (11, 12). IGF-1R is also highly expressed in a wide va-
riety of human cancers (13), and in rare cases is found to be
amplified at the DNA level (14). This overexpression seems
to have functional consequences, in particular the ability
to block apoptosis induced by a variety of agents or ad-
verse tumor microenvironments (15–17), and can also
confer invasive and metastatic capability in a mouse
model of pancreatic tumorigenesis (18). Epidemiological
and functional studies have also implicated the ligands
IGF-1 and IGF-2 in various aspects of cancer biology. In
particular, elevated levels of circulating IGF-1 have been
associatedwith increased risk of developing breast, prostate,
Fig. 1. Key components of the IGF-1R pathway. The ligands IGF-1 and IGF-2 are both capable of binding and stimulating the catalytic activity of the IGF-1R.
Bioavailability of IGF-1 is modulated by a family of IGFBPs, whereas bioavailability of IGF-2 is modulated both by the IGFBPs and by binding to the
IGF-2R, an event that leads to receptor-mediated internalization and degradation of IGF-2 in lysosomes. Upon binding by either IGF-1 or IGF-2,
the IGF-1R undergoes receptor cross-linking and autophosphorylation, leading to the creation of multiple docking sites for the adaptor proteins IRS-1,
IRS-2, and Shc. IRS-1 and IRS-2 binding results in activation of the class I phosphatidyl inositol 3′ kinase, whose catalytic activity is the conversion of
PIP2 to the lipid second messenger PIP3. This event recruits the AKT family of kinases to the plasma membrane, where they can be phosphorylated and
activated by PDK1 and the mTOR-containing complex mTORC2. Activated AKT then mediates a host of cell signaling events, including disinhibition
of the mTORC1 complex and increased protein synthesis and cell growth, increased conversion of glucose to glycogen via inhibition of GSK-3β, and
increased proliferation and survival by activation or inhibition of key effectors such as the Foxo transcription factors, p27, BAD, and BCL-2. In contrast,
Shc binding to activated IGF-1R results in stimulation of the RAS/MAP kinase pathway, which also leads to increased cell proliferation.
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Figure 2.  Key components of the IGF-IR pathway.  
The IGF-1 and IGF-2 ligands are both capable of binding and stimulating the 
catalytic activity of the IGF-IR.  Bioavailability of IGF-1 is modulated by a family of 
IGFBPs.  Upon binding either IGF-1 or IGF-2, the IGF-IR undergoes receptor cross-
linking and autophosphorylation, leading to the creation of multiple docking sites for 
the adaptor proteins IRS-1, IRS-2 and SHC.  IRS-1 and IRS-2 binding results in 
activation of the class I PI3 Kinase, whose catalytic activity is the conversion of 
PIP2 to the lipid messenger PIP3.  This event recruits the AKT family of kinases to 
the plasma membrane, where they can be phosphorylated and activated by PDK1 
and the mTOR-containing complex MTORC2.  Activated AKT then mediates a host 
of cell signaling events, including disinhibition of the mTORC1 complex and 
increased protein synthesis and cell growth, increased conversion of glucose to 
glycogen via inhibition of GSK-3B, and increased proliferation and survival by 
activation or inhibition of key effectors such as the FOXO transcription factors, p27, 
BAD, and BCL-2.  In contrast, Shc binding to activated IGF-IR results in stimulation 
of the RAS/MAP kinase pathway, which also leads to increased cell proliferation. 
Reprinted with permission from the American Association for Cancer Research, 
provided by the Copyright Clearance Center. Copyright 2010, American Association 
for Cancer Research. 
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1.8 IGF-IR Inhibitors 
IGF-IR has become an attractive target in the clinic over the last ten years, due to 
its central role in cancer cell signaling.  Various monoclonal antibodies and tyrosine 
kinase inhibitors (TKIs) against IGF-IR are under investigation for treatment of solid 
tumors (Chitnis et al., 2008).  Most antibody-based IGF-IR inhibitors function by 
blocking IGF-ligand binding to the receptor, decrease expression of IGF-IR at the 
cell surface by mediating receptor internalization, and blocking intracellular signaling 
primarily through PI3K/AKT pathway (Zha & Lackner, 2010).  It is believed that 
monoclonal antibodies are more specific, due to the amino-acid sequence similarity 
of tyrosine kinase domain which makes specificity of TKIs a significant issue 
(Rodon, DeSantos, Ferry, & Kurzrock, 2008).  Initial results of IGF-IR treatment in 
large clinical trials have not been as successful as hoped; however, anecdotal 
cases of individual positive responses to IGF-IR therapies have encouraged 
continued study into biomarkers that will enable selection of the best target 
population (Gombos, Metzger-Filho, Dal Lago, & Awada-Hussein, 2012).   
Picropodophyllin (PPP) is the only tyrosine kinase inhibitor currently available that 
can discriminate between insulin receptor and IGF-IR (Girnita et al., 2004).  PPP is 
thought to inhibit IGF-IR by utilizing the MDM2 E3 ligase, which is known to 
ubiquitinate the IGF-IR and causes its downregulation (R. Vasilcanu et al., 2008). 
1.9 In vivo models of brain metastasis 
Although brain metastasis studies typically rely on a combination between in vitro 
and in vivo experimental approaches to formulate conclusions, some researchers 
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have recently argued that in vitro and in vivo studies of the early steps of brain 
colonization from the bloodstream should only be studied in vivo (Lorger, Lee, 
Forsyth, & Felding-Habermann, 2011).  Behavior of breast cancer cells in in vitro 
cell adhesion and transendothelial migration analyses, for example, correlate poorly 
with the behavior of the same cells in in vivo brain metastasis models.  Since cells 
are injected in the carotid artery, our model of brain metastasis circumvents many 
anatomical barriers and primarily addresses the late stages of brain metastasis.  
1.10 Statement of problem, hypothesis and project goals 
The functional role of IGF-IR in primary breast cancer and breast cancer 
metastasis has been well documented by others.  Furthermore, Improta et. al. have 
found a correlation of phosphorylated IGF-IR in patient samples of brain metastases 
from breast cancer.  However, whether IGF-IR directly plays a functional role in the 
establishment of brain metastases has not been addressed.  It is possible that IGF-
IR activation in brain metastases is a result of the highly malignant primary and/or 
metastatic breast tumors from which they arise.  However, it is also possible that 
IGF-IR activation itself enables the establishment of breast cancer cells in the brain 
by means of a survival advantage.  Further studies are needed in order to discern 
whether IGF-IR provides a survival advantage to breast cancer cells in the brain.  
In the present study, we sought to address the biological relevance of IGF-IR 
signaling in the metastasis of breast cancer to the brain.  We hypothesized that 
IGF-IR activation confers a metastatic advantage and enables the outgrowth 
of breast cancer cells in the brain.  Figure 3 depicts a model of our hypothesis.  
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First, we test whether IGF-IR signaling plays a role in the metastatic potential of 
brain-seeking breast cancer cells in vitro. Using an in vivo experimental brain 
metastasis model, we found that ablation of IGF-IR expression can prevent the 
outgrowth of brain metastases, suggesting that this signaling pathway merits further 
study as a potential target for the treatment of breast cancer brain metastasis. 
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Figure 3.  Model depicting project hypothesis.  
Brain-seeking breast cancer cells overexpress the secreted form of IGFBP3, which 
may enhance the bioavailability of IGF-1 or independently activate IGF-I Receptor 
phosphorylation.  Once activated, IGF-IR recruits docking proteins such as IRS-2, 
which enable the assembly of protein complexes that transduce signaling 
downstream through the PI3K/AKT pathway.  IGFBP3 may also modulate the brain 
microenvironment in a paracrine manner, but future studies should explore that 
possibility in further detail.  
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2.1 Cell Culture 
All cancer cell lines were maintained at 37°C in a 5% CO2 incubator. Unless 
otherwise noted, cells were cultured in complete medium containing DMEM/F12 
with 10% fetal bovine serum (FBS) and penicillin/streptomycin. The human MDA-
MB-231Br (brain-seeking) cell line and its corresponding MDA-MB-231P (parental) 
cells were contributed by Dr. Patricia Steeg and previously described (Yoneda et 
al., 2001). The BT474 M1 (parental) and BT474 Br3 (brain-seeking) cell lines were 
established by Dr. Dihua Yu (MD Anderson, Houston, TX) and a detailed 
description of the BT474Br3 cell line will be published later by Dr. Yu’s group. Cell 
lines were validated by STR DNA fingerprinting using the AmpFlSTR Identifiler kit 
according to manufacturer instructions (Applied Biosystems). The STR profiles were 
compared to known ATCC fingerprints (ATCC.org), to the Cell Line Integrated 
Molecular Authentication database (CLIMA) version 0.1.200808 (Nucleic Acids 
Research 37:D925-D932 PMCID: PMC2686526) and to the MD Anderson 
fingerprint database. The STR profiles matched known DNA fingerprints or were 
unique. Cells were incubated with 50 ng/mL human recombinant IGF-1 (#I3769, 
Sigma) for the indicated time points in ligand-stimulation experiments. 
 
2.2 Immunoprecipitation and Western blotting 
Equal numbers of cells per sample well were seeded and cultured in complete 
medium and/or treated as specified. For analysis, cells were washed with PBS, 
trypsinized, and pelleted. Equal amounts of protein were resuspended in IP binding 
buffer (10x RIPA containing 0.5 M Tris-HCl (pH 7.4), 10% NP-40, 1.5 M NaCl, and 
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10 nM EDTA). Either Rabbit IgG (#sc-2027, Santa Cruz Biotechnology) or anti-IGF-
IRβ (#sc-462, Santa Cruz Biotechnology) were added at 4°C overnight. Lysates 
were incubated with Protein G agarose beads for 4 hr at 4°C, pulled down by 
centrifugation, and then washed extensively with IP binding buffer containing 
protease and phosphatase inhibitors. Immunoprecipitates were denatured using 
sample buffer containing β-mercaptoethanol, centrifuged, and the protein-containing 
supernatants were then analyzed by SDS-PAGE. Membranes were incubated with 
anti-IGF-IRβ-pY1131/InsRβ-pY1146 (#3021, Cell Signaling Technology), anti-IGF-
IRβ-pY1135 (#3918, Cell Signaling Technology), and anti-p-Tyr-100 (#9411, Cell 
Signaling Technology) to measure phosphorylation level of IGF-IR.  For IP-Western 
input controls and all other samples analyzed by SDS-PAGE, wells were loaded 
with 70 µg of protein.  Western blot membranes were probed with anti-IGFBP3 (C-
19; #sc-6003, Santa Cruz Biotechnology), anti-AKT (#9272, Cell Signaling 
Technology), anti-pAkt (S473; #9271, Cell Signaling Technology), anti-S6K1 (#sc-
230, Santa Cruz Biotechnology), anti-pS6K1 (T389; #9205, Cell Signaling 
Technology), and anti-tubulin (#T5168, Sigma). For IGFBP3 Western blots, 48-hr 
conditioned medium was collected and concentrated 40-fold using Millipore Amicon 
Ultra-4 centrifugal filters (Fisher). Equal protein amounts were loaded into each well 
of an SDS-PAGE.   
 
2.3 Flow Cytometry 
IGF-IR phosphorylation was measured by flow cytometry.  Cells were prepared as 
previously described (Krutzik & Nolan, 2003).  Briefly, cells were serum-starved for 
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24 hr and then fixed for 10 min at room temperature with 1.5% paraformaldehyde by 
adding it directly into the medium used to collect cells after trypsinization. Cells were 
pelleted, permeabilized by adding ice-cold methanol and vortexing vigorously, and 
then incubated for 10 min at 4°C.  Cells were then washed twice with staining buffer 
(PBS containing 1% BSA) and resuspended in staining buffer at 500,000 cells per 
100 µl.  Finally, cells were stained with AlexaFluor 647 mouse anti-IGF-1 Receptor 
(pY1131; #558588, BD Biosciences) and analyzed using the BC Gallios flow 
cytometer. Unstained cells were used as a control. All data were analyzed using the 
FlowJo version X software. 
 
2.4 Production of stable cell lines 
MDA-MB-231Br cells were first transduced with the luciferase expression vector 
pLenti CMV V5-LUC Blast w567-1 (plasmid #21474, Addgene) and the selected 
using blasticidin. Stable IGF-IR knockdowns (shIGFR) were obtained by 
transfection of MDA-MB-231Br cells with two lentiviral pLKO.1 constructs containing 
shRNA against IGF-IR target sequences, GAGACAGAGTACCCTTTCTTT and 
GCCGAAGATTTCACAGTCAAA (TRCN0000121135 and TRCN0000039675, 
respectively, Open Biosystems). MDA-MB-231Br control cells (Vector) were 
obtained by stable transfection with a pLKO.1 puro empty vector control plasmid 
(Sigma). Luciferase, shRNA, or control constructs were co-transfected with lentiviral 
packaging plasmids into 293T cells, and viral particles were harvested at 24 and 48 
hr post-transfection. MDA-MB-231Br cells were infected with virus for 48 hr in the 
presence of 5 µg/mL polybrene. Luciferase-expressing cells were first selected by 
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incubation in complete medium containing blasticidin (2 µg/ml) for 2 weeks. After 
stable luciferase-expressing MDA-MB-231Br cells were obtained, shRNA and 
control vector infections were carried out and stable clones were selected using 
culture medium containing puromycin (2 µg/ml) for 2 weeks.  Knockdown of IGF-IR 
was verified by Western blot. Luciferase expression was measured using the IVIS 
imaging system to ensure all cell lines retained similar expression level. 
 
2.5 Wound-healing assays 
MDA-MB-231Br shIGF-IR or shControl stable cells were seeded in a Costar 12-well 
dish (Sigma CLS3513) and cultured until confluent.  A wound was introduced using 
a 200-µl pipette tip, and cell migration was monitored using the Zeiss Axiovert 200M 
time-lapse microscope and 10x phase contrast objective. Images of specific 
positions were taken at 30-min intervals over 24 hr and recorded using the 
AxioVision 4.6 software. Relative migration was calculated by measuring wound 
area at different time points using ImageJ. 
 
2.6 Intracarotid mouse model of experimental brain metastasis 
Female Swiss nu/nu mice 8 weeks of age were purchased in-house from MD 
Anderson’s Department of Veterinary Medicine and Surgery – ERO Animal 
Resources.  Mice were anesthetized with ketamine/xylazine and inoculated with 
200,000 MDA-MB-231Br-shControl, -shIGFIR (B) or -shIGFIR (F) cells in 100 µl 
HBSS via injection into the right common carotid artery. Cells were verified to have 
a minimum of 95% viability prior to inoculation in mice. Development of brain 
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metastasis was observed once weekly by luciferase imaging using the IVIS imaging 
system by Caliper Life Sciences.  For imaging, mice were anesthetized by 
isofluorane/O2 and injected intraperitoneally with 100 µL D-luciferin (Caliper Life 
sciences). Ten minutes after D-luciferin injection, images of brain metastases were 
captured using the Living Image 3.2 software. To obtain brain tissues, mice were 
euthanized according to animal facility guidelines under CO2 asphyxiation followed 
by cervical dislocation. Brains were excised immediately following euthanasia and 
fixed in 10% neutral buffered formalin 24-48 hr at room temperature. Samples were 
then washed thoroughly with PBS and cut into sections across the coronal plane. 
Brain cross sections were paraffin embedded for analysis by immunohistochemistry 
(IHC). All animal procedures were performed under the guidelines approved by the 
Institutional Animal Care and Use Committee (IACUC) at MD Anderson Cancer 
Center. 
 
2.7 Immunohistochemistry (IHC) 
For IHC, a modified immunoperoxidase staining method from the avidin-biotin 
complex technique was used as described previously (Xia et al., 2004). Slides (4 
µm thick) were first deparaffinized. Following antigen retrieval, the slides were 
digested with 10 mM Tween 20 citrate buffer (pH 6.0).  The endogenous peroxidase 
activity was blocked by incubation in 0.3% hydrogen peroxide. The slides were then 
blocked with 10% normal goat or horse serum for 30 min and incubated overnight 
with primary antibodies, including anti-IGF-IR pAb (1:80 dilution; Santa Cruz 
Biotechnology), anti-IGF-IR pAb (1:50; Cell Signaling Technology), anti-phospho-
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AKT (Ser473; 1:100; Cell Signaling Technology), anti-ki-67 pAb (ready to use; 
Zymed); and anti-GFAP pAb (1:50; Cell Signaling Technology). After primary 
antibody hybridization, slides were incubated with biotinylated secondary 
antibodies, followed by incubation with avidin-biotin-horseradish peroxidase 
complex (Vector Laboratories). Antibody detection was performed with the 0.125% 
aminoethylcarbazole chromogen (AEC) substrate solution (Sigma). The slides were 
counterstained with Mayer’s hematoxylin (Sigma) and then mounted. For the 
negative control, all incubation steps were identical except that PBS was used 
instead of primary antibody. For the positive control, a previously identified strongly 
staining tumor tissue section was used. The prepared slides were examined by light 
microscopy. To ensure absolute objectivity of these IHC studies, experienced 
pathologists, who stained and evaluated primary tumor sections, conducted the 
experiments. The slides in which there was a scoring discrepancy >10% were re-
evaluated and reconciled on a two-headed microscope. 
 
2.8 Cell cycle analysis 
Equal cell numbers were seeded in complete medium overnight and were either 
untreated or treated with picropodophyllin (Sigma) at 1 µg/mL for 48 hr.  Cells were 
then washed with PBS, trypsinized, and fixed in 70% ethanol for 24 hr.  After 
fixation, cells were washed twice with PBS and incubated with 40 µg/ml propidium 
iodide to stain DNA and 0.5 µg/ml RNAseH to degrade RNA to prevent it from being 
included in the cell cycle analysis. Cell cycle was then analyzed using the BC 
Gallios flow cytometer.  
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2.9 Quantitative real-time PCR of IGFBP3 
RNA from MDA-MB-231P and MDA-MB-231br cells was extracted using the Qiagen 
RNEasy mini kit (Qiagen). cDNA was obtained by using the SuperScript First-
Strand System for RT-PCR (Life Technologies). Real-time PCR reactions were 
prepared with 1x iQ SybrGreen Supermix (Bio-Rad) and 0.250 nM forward and 
reverse primers. Cycling conditions consisted of annealing, amplification and melt 
steps using the Applied Biosystems Veriti real-time PCR thermal cycler. Relative 
gene expression was calculated by dividing the IGFBP3 expression value by the 
HPRT1 expression value. 
 
2.10 Transwell migration and invasion assay 
Migration assays were performed using a 24-well transwell plate (Corning) and 
invasion assays were performed using the 24-well BD BioCoat Matrigel Invasion 
Chambers (BD Biosciences) according to the manufacturer’s instructions. MDA-MB-
231P (25,000) or  MDA-MB-231Br (40,000) cells were seeded in the chamber 
inserts and allowed to migrate for 24 hr. Migrated cells were fixed with 4% 
paraformaldehyde, stained with crystal violet (0.1% in ethanol), and counted. 
Experiments were performed a minimum of 3 times in triplicate, and 5 fields of cells 
were counted at 10x magnification per chamber insert.   
 
2.11 Proliferation assays 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay of shIGF-
IR and shControl cells was performed by seeding cells overnight at a concentration 
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of 10,000 cells per well in a 96-well plate.  After 24, 48, and 72 hr, MTT reagent was 
added and cells were incubated at 37°C in 5% CO2 for 4 hr. Medium was then 
aspirated, and cells were lysed with DMSO and shaken gently for 1 hr at room 
temperature before measuring the optical density at 595 nm with a 
spectrophotometer. The growth of shIGF-IR stable transfectants was also measured 
by seeding cells at a concentration of 100,000 cells per well in a 6-well dish and 
counting cells using the Z1 Coulter Particle Counter (Beckman Coulter).  All wells 
for MTT Assay and cell counting experiment were seeded in triplicate and 
experiments performed a minimum of 3 times. 
 
2.12 Statistical analysis  
Significance in the brain metastasis-free survival curve was calculated using the 
Gehan-Wilcoxon test. All other samples were analyzed using a two-tailed student’s t 
test. Results with p < 0.05 were considered statistically significant.   
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CHAPTER 3 
 
THE ROLE OF TYPE I INSULIN-LIKE 
GROWTH FACTOR RECEPTOR IN BRAIN-
SEEKING BREAST CANCER CELLS 
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3.1 Brain-seeking breast cancer cells express higher amounts of IGF-I 
Receptor 
In order to assess the importance of IGF-IR in our model system, we were 
interested characterizing the expression profile of the receptor in our sets of 231 
and BT-474 parental and brain-seeking cell lines.  We performed a western blot of 
total IGF-IR expression in 231P/Br and BT474M1/Br3 cells, and found that IGF-IR is 
highly expressed in parental breast cancer cells, and expression is further increased 
in brain-seeking sublines (Figure 4, top).  Densitometric analysis was done using 
ImageJ software to confirm the increase in IGF-IR expression normalized to tubulin 
loading control (Figure 4, bottom).  Increased IGF-IR expression in brain-seeking 
cell lines suggested that this receptor may be enriched in highly metastatic cells. 
3.2 Type I IGFR is autophosphorylated in brain-seeking breast cancer cells 
Previous studies suggest that IGF-1 signaling and IGF-IR activation play a role 
in the brain specificity of metastatic breast cancer (Improta et al., 2011; Sierra et al., 
1997). To determine the relevance of IGF-IR activation in our model of brain 
metastasis, we characterized the activation profile of IGF-IR in parental MDA-MB-
231 (231P) and parental BT474 M1 breast cancer cells for comparison to their 
respective brain-seeking sublines, MDA-MB-231Br (231Br) (Yoneda et al., 2001) 
and BT474Br3.  One of the current limitations of studying the phosphorylated form 
of IGF-IR is the cross-reactivity of commercially available antibodies with 
homologous phosphorylation sites on the insulin receptor. To circumvent this issue, 
we first immunoprecipitated the IGF-IR β subunit with a specific antibody that does 
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not cross-react with the insulin receptor, followed by immunoblotting with phospho-
IGF-IR antibody against Tyr 1131, the earliest autophosphorylation site that is 
absolutely required for IGF-I ligand-dependent IGF-IR function (Kato et al., 1994). 
We found that 231Br and BT474Br3 cells had higher IGF-IR autophosphorylation 
compared to the parental cells under normal growth conditions in complete medium 
(Figures 5A and 5B). After normalizing each cell line’s phosphorylation signal to its 
own total IGF-IR protein band, autophosphorylation of IGF-IR was increased by 
27.4% and 21.6% in 231Br and BT474 Br3, respectively (Figures 5C and 5D). 
To confirm this observation and to obtain a more detailed picture of the IGF-IR 
activation profile in brain-seeking cells, we examined IGF-IRβ phosphorylation using 
flow cytometry with an Alexa647-conjugated phospho-Tyr1131-IGF-IRβ antibody. 
We found that both 231Br and BT474Br3 cell lines expressed more phosphorylated 
IGF-IR than parental breast cancer cells under normal growth conditions in 
complete medium (Figures 6A and 6B). An average of 36.4% of the 231Br cell 
population was positive for phospho-Tyr1131 IGF-IRβ, compared to 14.6% of 231 
parental cells (p < 0.005, Figure 6C, bottom left panel). Likewise, 81.9% of the 
BT474Br3 cell population was positive for phospho-Tyr1131 IGF-IRβ, compared to 
an average of 51.3% of the BT474 M1 parental cells (p < 0.05, Figure 6D, bottom 
right panel). In addition to the percentage of phospho-Tyr1131 IGF-IR positive cells, 
we also measured the median fluorescence intensity (MFI) of these populations, 
which refers to the shift in overall intensity of the phospho-Tyr1131 IGF-IRβ signal. 
Consistent with the results shown in Figure 6C and 6D, we observed an increase in 
MFI of the 231Br and BT474Br3 cell populations compared to the parental cells 
	   37	  
such that the MFI of 231Br cells was 3.24, compared to 2.1 in the 231 parental cells 
(p < 0.0005; Figure 6E) while the BT474Br3 cell lines exhibited a similar trend with 
an MFI of 7.29 compared to 4.38 in the parental BT474 cells (p < 0.05, Figure 6F). 
One possible explanation for the higher phospho-IGF-IR observed in brain-seeking 
cells in Figures 5 and 6 is the higher expression level of total IGF-IR protein 
detected in whole cell lysates (Figure 4). The flow cytometry data indicated that 
IGF-IR is autophosphorylated in a higher percentage of brain-seeking cells, and that 
the mean intensity of IGF-IR phosphorylation in these cells is also higher. 
Collectively, these findings demonstrated that the total protein level and 
autophosphorylation of IGF-IR is higher in brain-seeking cells than in parental 
breast cancer cells.  
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Figure 4 
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Figure 4.  IGF-IR expression profile of breast cancer cell lines and brain-
seeking subclones.  
Top, Western Blot of total IGF-IR expression in 231P/Br and BT474M1/Br3 cells.   
Bottom, densitometric analysis of IGF-IR bands from top panel, normalized to 
Tubulin. ImageJ software was used for analysis. 
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Figure 5 
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Figure 5. IGF-IR is activated in brain seeking breast cancer cells.  
A and B, Immunoprecipitates of IGF-IRβ from lysates of the parental MDA-MB-231 
and BT474 breast cancer cells (231P, BT474 M1) and their respective brain-
seeking sublines (231Br, BT474 BR3), were analyzed by SDS-PAGE and 
immunoblotted with antibodies against the IGF-IR Tyr1131 autophosphorylation 
site. Cells were serum-starved overnight prior to lysis. 
C and D, Quantification of IGF-IR-pY1131 expression in 231P/Br, BT474M1/Br3 
cells after normalization to total IGF-IR IP band.  Phosphorylation of IGF-IR 
increased in both brain seeking cell lines. 
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Figure 6 
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Figure 6. IGF-IR is activated in brain seeking breast cancer cells.  
A and B, Flow cytometric analysis of IGF-IR activation in 231P & BT474 M1 breast 
cancer cells and respective brain-seeking sublines, 231Br and BT474 Br3, shown in 
Figure 5. Cells were serum-starved for 24h and stained with AlexaFluor 647-
phospho Y1131 IGF-IR antibody.  
C and D, Quantitation of flow cytometric analyses of fluorescent cells per group is 
shown below each panel. Values shown represent mean ± SEM from 3 replicates 
(*, p < 0.05, ***, p < 0.0005). 
E and F, Median Fluorescence Intensity shift captured by flow cytometric 
measurement of parental and brain-seeking breast cancer cells stained with 
Tyr1131-IGFR-Ax647 antibody. Values represent mean ± SEM (*, p < 0.05, ***, p < 
0.0005). 
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3.3 IGF-1 ligand stimulation drives migration and invasion in brain-seeking 
cells 
In order to test whether IGF-IR autophosphorylation and downstream functions 
are mediated by IGF-1 ligand bioavailability in brain-seeking cells, we examined the 
malignancy of brain-seeking cells under IGF-1 ligand stimulation.  In order to 
evaluate whether 231P and 231Br cells are IGF-1-responsive, we first serum-
depleted cells overnight in order to minimize the IGF-IR autophosphorylation 
observed in Figure 5A.  We then stimulated serum-depleted 231P and 231Br cells 
with IGF-1 and immuniprecipitated of the IGF-I Receptor. In the IGF-IR 
immunoprecipitates, we observed phosphorylation at Tyr1135 in the 231Br but not 
231P cells, suggesting that brain-seeking cells are driven by ligand stimulation 
(Figure 7A). We also examined the phosphorylation status of the insulin-receptor 
substrate (IRS)-1 and -2, which are immediately activated upon IGF-IR activation.  
IRS-2 is known to mediate motility and pro-metastatic behavior of IGF-IR in breast 
cancer cells (Jackson et al., 2001), and indeed, only IRS-2 was phosphorylated 
upon IGF-1 ligand stimulation in 231Br cells but not the parental cells (Figure 7B). 
Downstream of IGF-IR, AKT was also phosphorylated at Ser 473 upon IGF-1 ligand 
stimulation in 231Br cells but not 231P cells (Figure 7C).  The differential AKT 
activation in the two cell types may be due to the serum-free medium used in this 
experiment.  It is possible that the stimulation time (15 minutes) or IGF-1 
concentration may not be high enough to induce AKT Ser 473 phosphorylation in 
parental cells, but the 231 Br cells were sensitive to IGF-1 ligand due to IGF-IR 
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overexpression.  Taken together, these data suggest that the IGF-1 ligand activates 
IGF-IR axis signaling molecules in brain-seeking cells. 
 Next, we performed a transwell assay to measure the response of 231Br cells 
to IGF-1 ligand as a chemoattractant and found that overnight incubation with IGF-1 
stimulated the migration of 231Br but not 231P cells under low serum conditions 
(0.2% FBS DMEM; Figure 8A with quantification in the lower panel).  Similarly, 
231Br cells were more invasive in a matrigel invasion assay when IGF-1 ligand was 
present as a chemoattractant (Figure 8B with quantification in the lower panel). In 
our experience, only the 231Br cells responded to IGF-1 ligand stimulation under 
low serum conditions. We speculate that under low serum conditions, IGF-1 ligand 
stimulation is not sufficient to induce migration and invasion in 231 parental cells, 
but 231Br cells are more sensitive to IGF-1 ligand stimulation due to their higher 
levels of IGF-IR expression. Thus, we concluded that the IGF-IR signaling and pro-
metastatic functions of brain-seeking cells are likely mediated by IGF-1 ligand and 
further amplified by higher expression of IGF-IR protein. 
 Future studies should delve deeper into the molecular mechanisms of 
increased IGF-IR expression of 231Br cells in further detail.  Dysregulation of IGF-
IR expression in cancer is rarely a result of gene amplification or activating genetic 
mutations.  Rather, IGF-IR protein is regulated by a variety of tumor suppressor 
proteins at the pre- and post-transcriptional level.  For example, PTEN is known to 
inhibit the synthesis of IGF-IR precursor, as well as inactivate AKT (Tanno et al., 
2001).  Loss of PTEN results in increased AKT phosphorylation as well as 
increased IGF-IR protein translation (Tanno et al., 2001).  Similarly, mutations of 
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p53 can lead to increased IGF-IR promoter activity and mRNA transcript levels 
(Werner, Karnieli, Rauscher, & LeRoith, 1996).  The IGF-IR promoter is also 
repressed by BRCA1 (Maor, Abramovitch, Erdos, Brody, & Werner, 2000) and VHL 
protein is a post-translational regulator by sequestration of HuR protein that results 
in de-stabilization of IGF-IR mRNA (Yuen et al., 2007).  p53, BRCA1, and VHL are 
all known to downregulate IGF-IR transcription through interaction with Sp1 
transcription factor and disrupting its binding to the IGF-IR promoter (Abramovitch, 
Glaser, Ouchi, & Werner, 2003; Ohlsson, Kley, Werner, & LeRoith, 1998; Yuen et 
al., 2007). Furthermore, Wilms Tumor Protein 1 (WT1) can also bind the IGF-IR 
promoter directly on consensus sites on either side of the promoter through its zinc 
finger domain and repress transcription (Werner et al., 1993).   
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Figure 7 
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Figure 7.  IGF-IR activation is IGF-1 ligand-dependent in brain-seeking cells.  
A, 231P and 231Br cells were serum-starved overnight, and then stimulated with 50 
ng/ml IGF-1 for 15 min. IGF-IR was immunoprecipitated and then immunoblotted 
with phospho-Y1135-IGF-IR antibody.  
B, Immunoprecipitates of IRS-1 and IRS-2 proteins from serum-starved 231P and 
231Br cells, unstimulated or stimulated with 50 ng/ml IGF-1 for 15 min.   
C, Western blot analysis of whole cell lysates of 231P and 231Br cells after 
stimulation with IGF-1.
	   49	  
 
 
Figure 8 
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Figure 8.  IGF-1 stimulation drives in vitro migration and invasion in brain-
seeking breast cancer cells.   
A, Transwell migration assay of cells incubated for 24h in low serum with or without 
IGF-1 as a chemoattractant (top panel), quantitative analysis of relative cell invasion 
(bottom panel).  
B, Matrigel invasion assay of cells incubated for 24h in low serum with or without 
IGF-1 as a chemoattractant (top panel), quantitative analysis of relative cell invasion 
(bottom panel). Bars represent mean ± SEM. 
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3.4 Secreted form of IGFBP3 is overexpressed in brain-seeking cells 
Since the basal level of IGF-IR autophosphorylation in 231Br and BT474Br3 
cells is much higher under normal culture conditions, we asked whether the IGF-IR 
signaling axis is constitutively activated in an autocrine manner, either dependent or 
independent of IGF-1 ligand. Along with IGF-1 ligand, IGFBP3 is one of the major 
regulators of receptor activity in the IGF-IR signaling axis and a major binding 
protein of IGF-1 ligand that both potentiates and inhibits its interaction with IGF-IR in 
different cancers (Firth & Baxter, 2002; Martin, Lin, McGowan, & Baxter, 2009; Xi et 
al., 2006). In Hs578T breast cancer cells, IGFBP3 promotes attachment and 
survival on fibronectin (McCaig, Perks, & Holly, 2002), which is present in the 
perivascular space of the brain microenvironment and known to promote the growth 
of breast cancer cells in the brain (Carbonell, Ansorge, Sibson, & Muschel, 2009). 
However, IGFBP3 has also been reported to modulate IGF-IR phosphorylation 
independently of IGF-1 (Martin & Baxter, 2011; Schedlich & Graham, 2002). When 
we examined the IGFBP3 mRNA expression level in 231Br cells, we found that it is 
expressed 25-30 fold more than in 231P (Figure 9A). While IGFBP3 is traditionally 
studied as a secreted protein, it is known to carry out some of its functions 
intracellularly (Grkovic et al., 2012; Paharkova-Vatchkova & Lee, 2010). We first 
analyzed the levels of secreted IGFBP3 by collecting the conditioned medium of 
231P and 231Br cells. As a secreted protein, IGFBP3 exists in a non-glycosylated 
form (29kDa), 2N-glycosylated (40kDa), and 3N-glycosylated (45kDa) forms (Firth & 
Baxter, 1999). Based on the mRNA expression levels, we expected that the protein 
levels of IGFBP3 would be higher in brain-seeking cells. Indeed, as shown in Figure 
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9B, the wide IGFBP3 band indicates that all three glycosylated forms are highly 
secreted in 231Br cells but were undetectable in 231P cells. We also analyzed the 
levels of intracellular IGFBP3 and found no difference in expression between 231P 
and 231Br cells (Figure 9C). These results suggest that IGFBP3 exerts its function 
in 231Br cells in an extracellular autocrine manner. 
We did not test the molecular mechanism behind IGFBP3 observed in our 
model system, but it is known that IGFBP3 expression is stimulated by IGF-1 ligand 
(57).  IGFBP3 transcription is also regulated by promoter methylation and directly by 
the p53 tumor suppressor binding both in the promoter region and intronically 
(Hanafusa et al., 2005; Torng et al., 2009).  Furthermore, Vitamin D Receptor (VDR) 
binds the IGFBP3 promoter either alone or in association with Retinoid X, in order to 
enhance its transcription (Peng, Malloy, & Feldman, 2004).  Interestingly, VDR 
expression is also closely tied to IGF-IR signaling, and its expression is regulated by 
IGF-1 ligand stimulation (Welsh et al., 2002).  Therefore, we hypothesize that the 
IGFBP3 is overexpression observed in 231Br cells is a result of an autocrine 
positive feedback loop that is stimulated by enhanced IGF-IR pathway activation 
through IGF-1 signaling.  Further studies should test this hypothesis and elucidate 
the molecular mechanism of IGFBP3 regulation in our model system. 
3.5 Secreted IGFBP3 level correlates with autocrine IGF-IR activation in brain-
seeking cells 
In this study, we sought to measure the intrinsic properties acquired by 231Br 
cells that may be responsible for their enhanced ability to attach to and survive in 
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the brain parenchyma to a greater degree than the 231 Parental cell line.  Since we 
observed a dramatic overexpression of IGFBP3 in 231Br cells, our goal was to 
determine if IGFBP3 is functionally significant in promoting IGF-IR activation.  To 
test this, we knocked down the expression of IGFBP3 by transiently transfecting 
231Br cells with two different IGFBP3 siRNAs (Figure 10A) and analyzed the 
receptor autophosphorylation under normal growth conditions in complete medium. 
Knockdown of IGFBP3 by two siRNAs potently inhibited IGF-IR Tyr phosphorylation 
(Figure 10B).  A similar inhibitory effect was observed by flow cytometry on the 
phosphorylation of Tyr-1131-IGF-IR (Figure 10C), suggesting that IGFBP3 
stimulates IGF-IR activation in an autocrine manner.  Our study tested whether 
IGFBP3 confers enhanced intrinsic IGF-IR activation, which may result in a survival 
advantage when 231Br cells arrest in the brain parenchyma.  Indeed, is possible 
that the properties measured in this study may be equally important for metastasis 
to the lymph nodes, bone, or lung for example.  In order to specifically test the 
importance of IGFBP3/IGF-IR signaling in brain-specific metastasis, it would be of 
great interest to study effect of brain-derived IGF-1 ligand and IGFBP3 on IGF-IR 
activation and 231Br cell migration/invasion.  Although our study does not rule out 
whether IGFBP3/IGF-IR pathway is also involved in other organ metastases of 
breast cancer cells, it does highlight that in a heterogeneous population of breast 
cancer cells that arrest in the brain parenchyma, those cells that contain IGFBP3 
overexpression and subsequent IGF-IR pathway activation possess a survival 
advantage in the brain microenvironment, as discussed in the following Chapter.  
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The significance of IGFBP3/IGF-IR in the honing of breast cancer cells to the brain 
should be the subject of future studies.  
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Figure 9 
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Figure 9. The secreted form of IGFBP3 is overexpressed in brain-seeking 
breast cancer cells. 
A, Real-time quantitative RT-PCR of IGFBP3 in 231P and 231Br cells. Data are 
expressed as relative expression as a ratio to housekeeping gene HPRT1 
expression.   
B, Western blot analysis of secreted IGFBP3 protein in the conditioned medium of 
231P and 231Br cells. Equal cell numbers were incubated in serum-free medium for 
48 hr, and then the conditioned medium was collected and concentrated by 40-fold.  
C, Western blot analysis of IGFBP3 protein in lysates of 231P and 231Br cells. 
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Figure 10 
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Figure 10. IGFBP3 knockdown results in decreased IGF-IR activation in brain 
seeking cells.  
A, Conditioned medium of 231Br cells transiently transfected with control or IGFBP3 
siRNAs for 48 hr. Medium was concentrated by 40-fold and the protein expression 
of IGFBP3 was analyzed using Western blot.  
B, IGFBP3 knockdown downregulates IGF-IR phosphorylation. Cells were 
transfected with either control or IGFBP3 siRNAs. IGF-IR was immunoprecipitated 
(IP) and immunoblotted with phospho-Tyr antibody. Whole cell lysate (WCL) was 
used as input control.  
C, Flow cytometric analysis of 231Br cells after IGFBP3 knockdown. Cells were 
transfected with either control or IGFBP3 siRNAs, and stained with AlexaFluor 647-
phospho Y1131 IGF-IR antibody. IGF-IR phosphorylation decreased in the siRNA 
groups. 
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CHAPTER 4 
 
IN VITRO AND IN VIVO EFFECTS OF TYPE 
I INSULIN-LIKE GROWTH FACTOR 
RECEPTOR ABLATION IN BRAIN 
SEEKING BREAST CANCER CELLS 
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4.1 Transient knockdown of IGF-IR impairs wound healing in 231 brain-
seeking cells  
In order to determine the biological relevance of IGF-I Receptor in brain-seeking 
cells, we transiently transfected small interfering RNAs targeting the IGF-IR, and 
evaluated the cells’ ability to close the gap in a wound healing assay.  The wound-
healing assay measures cell motility, as well as the degree of cell-cell and cell-
matrix interactions in a cell monolayer (Rodriguez, Wu, & Guan, 2005).  Figure 11A 
is a control showing the efficiency of IGF-IR knockdown achieved by a universal 
negative control siRNA, and two different IGF-IR siRNAs in both 231 parental and 
brain-seeking lines.  Figure 11B shows time-lapse images at 0, 12, 24, and 48 
hours after introduction of the wound, and the 231Br cells transfected with IGF-IR 
siRNAs had significantly impaired wound healing ability.  The impaired ability of 
cells to migrate at the leading edge of the wound also suggests that IGF-IR 
knockdown may result in stronger cell-cell interactions between 231Br cells, and 
thus render them less metastatic. 
4.2 Transient knockdown of IGF-IR inhibits IGF-1-mediated AKT 
phosphorylation in brain seeking cells. 
To further validate whether IGF-IR knockdown plays a significant role in the 
intracellular signaling of 231 brain-seeking cells, we transfected both parental and 
brain-seeking 231 cells with IGF-IR siRNA and observed the effect of IGF-1 ligand 
stimulation at 48 hours after transfection.  As in Figure 7C, IGF-1 ligand stimulation 
induced AKT Ser473 phosphorylation of 231Br cells but not parental cells.  In 
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support of our hypothesis, IGF-IR siRNA inhibited AKT Ser473 phosphorylation in 
231 Br cells (Figure 12).  Therefore, we concluded that IGF-IR is important for 
intracellular signaling of brain seeking breast cancer cells. 
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Figure 11 
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Figure 11. Transient knockdown of IGF-IR inhibits migration of brain-seeking 
cells 
 
A, Western blot of lysates from 231P and 231Br cells collected 72 hours after siRNA 
transfection, the timepoint when siRNA shows the highest knockdown efficiency. 
 
B, Wound healing assay of 231Br cells.  Cells were transfected with Control siRNA 
or IGF-IR siRNA #1 or #2, allowed to recover overnight and then re-seeded in a 
monolayer overnight in a 12-well dish for wound healing assay.  Scratch wound was 
introduced at 48 hours after siRNA transfection, and wound closure was captured 
by time-lapse microscopy over the next 36 hours.  
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Figure 12 
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Figure 12. Transient knockdown of IGF-IR downregulates IGF-1-induced AKT 
activation 
231P and 231Br cells were transiently transfected with control, IGF-IR #1 or IGF-IR 
#2 siRNAs and stimulated with 50ng/mL of IGF-1 ligand for 15 minutes at 48 hours 
after transfection.  IGF-IR knockdown efficiency and AKT Ser473 phosphorylation 
were observed by western blot. 
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4.3 Stable knockdown of IGF-IR in brain-seeking breast cancer cells inhibits 
cell proliferation in vitro 
 In order to study the relevance of IGF-IR in the development of brain metastasis 
in vitro, and to follow up on our transient siRNA knockdown experiments (Figures 11 
and 12), we developed a model system using 231Br cells stably expressing 
luciferase and either empty vector (control) or IGF-IR shRNA. Of six sh-IGFR 
knockdown cell lines generated, two IGF-IR knockdown clones, shIGF-IR (B) and 
shIGF-IR (F), were selected for further characterization for comparison with the 
vector clone (vector). We first verified that IGF-IR was knocked down and AKT-
Ser473 phosphorylation was reduced (Fig. 13A).  To further assess the in vitro 
biological significance of IGF-IR knockdown in brain-seeking cells, we measured 
cell proliferation of knockdown and control cells using an MTT assay. As shown in 
Figure 13B, IGF-IR knockdown cells proliferated more slowly at all three time points. 
Moreover, we measured the cell growth of IGFR knockdown and vector control cells 
over a 72-hr period and calculated the total cell number. In agreement with the MTT 
assay results, IGF-IR knockdown cells grew more slowly than vector control cells 
(Fig. 13C). 
 
4.4 Stable knockdown of IGF-IR in brain-seeking breast cancer cells 
attenuates their migratory and invasive potential in vitro 
Next, we examined the effect of IGF-IR knockdown on the in vitro properties 
that are used as surrogate measures of metastatic potential of 231Br cells.  We first 
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used a wound-healing assay to determine the effect of IGF-IR knockdown on 
migration and found that IGFR knockdown cells were less efficient at closing the 
wound than the vector control cells, indicating both reduced motility and an increase 
of cell-cell adhesion in 231Br cells  (representative images shown in Figure 14A and 
quantification shown in Figure 14B).  To determine the effect of IGF-IR knockdown 
on the invasive potential of 231Br cells, we performed a matrigel invasion assay. 
Consistent with our hypothesis, we found that IGF-IR knockdown indeed attenuated 
the invasiveness of 231Br cells (representative images shown in Figure 14C and 
quantification shown in Figure 14D).  Taken together, these data demonstrate that 
the loss of IGF-IR expression and subsequent inactivation of its downstream 
signaling molecules attenuate the vitro invasive phenotypes, including proliferation, 
migration/motility and invasiveness, while enhancing in vitro cell-cell adhesion of the 
brain-seeking cells. 
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Figure 13  
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Figure 13. IGF-I Receptor knockdown in brain-seeking breast cancer cells 
suppresses proliferation in vitro.  
A, Immunoblot of IGF-IRβ and AKT total and phospho-Ser473 expression in 231Br 
cells stably transfected with control shRNA (vector) or IGF-IRβ shRNA (shIGF-IR B 
and F clones).  
B, MTT assay of control and IGF-IR beta knockdown cells at 24, 48 and 72 hr. 
Values represent mean ± SEM.  
C, Vector control and shIGF-IR 231Br cells were seeded 100,000 cells per well and 
were counted after 72 hr. 
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Figure 14 
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Figure 14. IGF-I Receptor knockdown in brain-seeking breast cancer cells 
suppresses cell migration and invasion in vitro. 
A, Wound-healing assay of vector and shIGF-IR 231Br cells. Images are 
representative of triplicates at 0 and 21 hr.   
B, Quantitative measurement of wound closure area from (A). Data were calculated 
from one representative experiment out of three performed.  
C, Matrigel invasion assay of vector and shIGF-IR 231Br cells performed in triplicate 
over 24 hr with complete medium as a chemoattractant.  
D, Quantitative analysis results of one representative experiment out of three 
performed in triplicate from (C). Values represent mean ± SEM.
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4.5 IGF-IR knockdown delays the outgrowth of brain metastases in vivo 
 To further characterize the functional consequences of IGF-IR knockdown on 
the development brain metastasis in vivo, we performed an experimental brain 
metastasis assay as described in Chapter 2. Stable 231Br-Vector, 231Br-shIGF-IR 
(B), and 231Br-shIGF-IR (F) cells were inoculated in the carotid artery of female 
swiss nu/nu mice, and brain metastasis development was monitored for 12 weeks. 
After the first 4 weeks, mice in the vector group developed physiological symptoms 
of brain metastases, such as weight loss, crouching, lethargy and/or disorientation.  
Figure 15 shows representative bioluminescence images of brain metastasis 
formation in mice from each experimental group during weeks 1-4.  Mice inoculated 
with 231Br cells with IGF-IR knockdown demonstrated significantly longer survival 
than those in the vector group (Figure 16A). Mice in both knockdown groups also 
developed brain metastases, albeit significantly later than the vector group (p < 
0.05).  The vector group mice had a median survival of 46 days while the shIGF-IR 
(B) and shIGF-IR (F) groups had median survival of 77 days and 55.5 days, 
respectively (Figure 16B).  
 
4.6 H&E and IHC analysis of mice that developed brain metastases 
Brain sections of representative mice from each group (n=3 each Vector and 
shIGF-IR (B); n=2 shIGF-IR (F)) were also analyzed by H&E staining (Figure 17A) 
and IHC for the expression of IGF-IR (Figure 17B) and AKT-pSer473 (Figure 17C) 
proteins. All mice included in the analysis were sacrificed at later time points (5-10 
weeks after intracarotid inoculation).  H&E staining revealed visible brain 
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metastases in most brain sections analyzed, although metastases from the IGF-IR 
knockdown groups were generally smaller in size than the vector group (Figure 
17A) with the exception of one sample from the shIGFR (B) group (not shown). 
Most metastases expressed IGF-IR protein (Table 1) although metastases in the 
shIGF-IR (B) and shIGF-IR (F) groups expressed lower levels of IGF-IR protein than 
the vector group (Figure 17B).  Expression of AKT-pSer473 likewise correlated 
positively with IGF-IR expression levels, with the vector group expressing the 
highest level of AKT-pSer473 and IGF-IR knockdowns expressing the lowest 
(Figure 17C). These results imply that in a heterogeneous starting population of 
IGF-IR knockdown cells, those that retain IGF-IR and AKT-pSer473 expression are 
able to survive and establish tumors within the brain microenvironment in a process 
of positive selection. 
 
4.7 Brain metastases induce reactive astrocytes 
Furthermore, it has previously been reported that metastatic brain tumors cause 
the activation of astrocytes in the brain microenvironment, resulting in the support of 
tumor growth and vascularization (Yoshimine et al., 1985). The expression of glial 
fibrillary acidic protein (GFAP) is a marker of this astrocytic activation, and IHC 
staining revealed that the brain tissue surrounding brain metastases expressed high 
amounts of GFAP (80% positive cells control group, 52%-58% positive cells shIGF-
IR groups, Table 1 and Figure 18). Remarkably, approximately 5-10% of GFAP 
positive cells infiltrated the edges of the tumor, suggesting that the activation and 
infiltration of astrocytes is associated with the growth of IGF-IR positive brain tumors 
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(Figure 18, white arrows).  Interestingly, studies by Fidler et al. found that reactive 
astrocytes play a role in the resistance of melanoma cells to chemotherapy (Q. Lin 
et al., 2010).  Future studies should investigate the functional significance of GFAP 
activation and its implications on the effect of tumor cell modulation of the brain 
microenvironment. 
 
4.8 IGF-IR positive brain metastases highly express nuclear proliferation 
marker ki-67 
 In addition to IGF-IR expression, the metastases we detected also expressed 
the nuclear proliferation marker ki-67 (Figure 19). Tumors from the control group 
had an overall higher percentage of ki-67 positive cells compared with those from 
the shIGF-IR (B) and shIGF-IR (F) groups (Table 1). Although the IGF-IR 
knockdown cells eventually formed brain tumors, these metastases were less 
proliferative than the vector control tumors at the time of mouse morbidity. 
 
4.9 Heterogeneous effects of IGF-IR knockdown on the growth of mammary 
fat pad tumors 
In order to determine whether IGF-IR knockdown in 231Br cells inhibited tumor 
cell proliferation in vivo, we inoculated 231Br Vector and 231Br-shIGF-IR (B) and 
231Br-shIGF-IR (F) into the mammary gland of nude mice.  Tumors were measured 
bi-weekly for 8 weeks and the diameters are shown in Figure 20.  The group of mice 
inoculated with 231Br-Vector cells behaved as expected, with tumor volumes 
gradually increasing over time.  The 231Br-shIGF-IR (B) experimental group had 
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remarkably no tumor formation over the 8 weeks, while the 231Br-shIGF-IR (F) 
group behaved very closely to the Vector group.  We hypothesized that the 
difference in proliferation may be due to the different levels of IGF-IR knockdown in 
each cell line.  As shown in Figure 13A, the sh-IGFR (B) cell line had complete IGF-
IR knockdown, while the shIGF-IR (F) cell line did not have complete knockdown of 
IGF-IR protein.  This suggests that even low amount of IGF-IR is sufficient to 
support cell proliferation of 231Br cells in vivo, at least in the mammary fat pad.  
Indeed, the IHC staining in Figure 21 confirms that the mammary fat pad tumors 
from mice in the shIGF-IR (F) group expressed lower amounts of IGF-IR protein, but 
developed normal mammary tumors as in the Vector group.  
Thus, partial IGF-IR knockdown is not sufficient to prevent in vivo survival of 
231Br cells.  This result could offer an explanation why some of the mice inoculated 
with both 231Br knockdown cell lines eventually developed brain metastases 
(Figures 16), and why the observed metastases expressed IGF-IR (Figure 17).  This 
result also raises questions about our experimental brain metastasis model.  In 
particular, whether factors other than IGF-IR-driven proliferation and survival of cells 
in vivo are at play in the development of brain metastasis, such as interactions with 
the brain microenvironment and/or MET which could be necessary for successful 
brain colonization. 
In order to test whether the inhibition of mammary fat pad tumor formation in the 
shIGF-IR (B) cell line was indeed due to the complete IGF-IR knockdown achieved 
in this cell line, it would be useful to repeat the experiment side-by-side with 
additional conditions.  In particular, we could test our hypothesis that incomplete 
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IGF-IR inhibition is insufficient for inhibition of in vivo cell proliferation in the 
mammary fat pad by adding several 231Br-Vector control groups with the addition 
of incremental doses of the IGF-IR inhibitor PPP.  In this setting, there should be an 
inverse relationship between tumor volumes and PPP concentrations if our 
hypothesis is correct that IGF-IR expression level dictates 231Br cell survival and 
proliferation in vivo.  Confirmation of our hypothesis would imply that survival of 
231Br shIGF-IR (B) cells in our brain metastasis model is a result of a re-expression 
of IGF-IR protein in our shIGF-IR cell lines, perhaps by epigenetic modulation, since 
we know that we started with a population with complete IGF-IR knockdown (Figure 
13A).  Another possibility is that IGF-IR is not the only factor dictating in vivo cell 
proliferation and brain metastasis in our model, in which case microenvironmental 
factors such as the induction of MET may be at play.  Both possibilities could 
account for the differences in brain metastasis development evidenced in the 
shIGF-IR (B) group, where 5 out of 8 mice (62.5%) eventually bypassed the barrier 
posed by IGF-IR knockdown, and the remaining 3 mice (37.5%) never developed 
brain metastases (Figure 16).  We originally hypothesized that IGF-IR knockdown in 
shIGF-IR (B) cells would result in complete inhibition of brain metastasis, but our 
results suggest an epigenetic modulation of IGF-IR expression and perhaps other 
IGF-IR-independent mechanisms of cell survival such as MET in the brain 
microenvironment. Further testing using the experiment proposed in this section, 
and the investigation of EMT/MET markers in our brain metastasis and mammary 
fat pad models would help to discern between these two possibilities. 
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Figure 15 
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Figure 15. IGFR knockdown delays brain metastasis development in vivo. 
Mice were anesthetized and injected with 200,000 231Br cells in the carotid artery; 
231Br-Luc-Vector (n=9), 231Br-Luc-shIGF-IR (B) (n=8), and 231Br-Luc-shIGF-IR 
(n=8).  Mice were imaged the day after surgery to ensure cells were arrested in the 
brain capillary.  Brain metastasis progression was monitored weekly by imaging with 
the IVIS imaging system following intraperitoneal administration of D-Luciferin. 
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Figure 16 
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Figure 16.  IGF-IR knockdown increases survival of mice bearing brain 
metastases. 
 
A, Survival curve of mice injected with 231Br cells stably expressing IGF-IR shRNA 
or vector shRNA. Mice were monitored weekly and sacrificed when moribund. 
shIGF-IR(B) and shIGF-IR(F) groups had significantly longer survival, p = 0.0012 
and p = 0.0133, respectively.   
 
B, Median survival of each group from (A). 
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Figure 17 
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Figure 17.  IGF-IR knockdown delays brain metastasis in vivo.  
H&E and IHC staining of representative brain metastases from each group.  
 
A, H&E panels: dark red = tumor tissue; blue = nucleus; light red = negative.   
 
B and C, IGF-IR and AKT-pSer473 panels, respectively: red = positive; blue = 
nucleus.  Images were taken at 200x and 400x magnification, as indicated. 
 
 
	   83	  
Figure 18 
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Figure 18. IHC staining of GFAP of brain metastases of mice inoculated with 
Vector, shIGF-IR (B) and shIGF-IR (F) 231Br cells.  GFAP: dark red/brown = 
positive; blue = nucleus; black arrows = tumor cells; white arrows = tumor-infiltrating 
astrocytes. Images were taken at 200x and 400x magnification, as indicated. 
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Figure 19 
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Figure 19. IHC staining of ki-67 of brain metastases of mice inoculated with 
Vector, shIGF-IR (B) and shIGF-IR (F) 231Br cells.  Red = nuclear ki-67 staining.  
Images were taken at 200x and 400x magnification, as indicated. 
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Table 1 
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Table 1. Summary of H&E and IHC staining of brain metastases of mice inoculated 
with Vector, shIGF-IR (B) and shIGF-IR (F) 231Br cells. Higher IGF-IR and ki-67 
staining appears to correlate with formation of larger metastases. 
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Figure 20 
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Figure 20.  Tumor formation in the mammary fat pad is heterogeneous in IGF-
IR knockdown cell lines. 
 
Female nude mice were inoculated with 231Br-Vector (n=10), 231Br-shIGF-IR (B) 
(n=10), or 231Br-shIGF-IR (F) (n=10) cells in the mammary fat pad.  Tumor growth 
was measured bi-weekly for eight weeks beginning on the second week, and 
average tumor volumes are plotted.  
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Figure 21 
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Figure 21.  Tumor formation in the mammary fat pad from IGF-IR knockdown 
cells is heterogeneous.  
H&E and IHC staining of representative mammary fat pad tumors from each group.  
 
A, H&E panels: dark red = tumor tissue; blue = nucleus; light red = negative.   
 
B and C, IGF-IR: red = positive; blue = nucleus.  Images were taken at 200x and 
400x magnification, as indicated. 
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4.10 Inhibition of the IGF-IR by picropodophyllin induces G2/M cell cycle 
arrest and inhibits downstream signaling and biological function 
 Several monoclonal antibodies and TKIs against IGF-IR are currently under 
study in the clinical setting and have shown promise in the treatment of solid tumors 
(Chitnis et al., 2008). Picropodophyllin (PPP) causes an induction of cell cycle arrest 
in the G2/M phase and is the only inhibitor that can specifically inhibit IGF-IR 
without affecting the insulin receptor (Stromberg et al., 2006).  PPP also leads to 
inhibition of cell growth, migration and invasion, and metastasis in a PI3K/AKT-
dependent manner (Girnita et al., 2004; Menu et al., 2006; D. Vasilcanu et al., 
2004).  We analyzed the effect of PPP on the cell cycle and demonstrated that PPP 
induces an increase of cells in G2/M phase by 86% in 231Br cells and 35% in 
BT474Br3 cells (Figure 22).  This result is consistent with other published studies 
that demonstrated arrest in the G2/M transition upon PPP treatment (Stromberg et 
al., 2006),(Karasic, Hei, & Ivanov, 2010).  However, PPP-induced G2/M cell cycle 
arrest is an interesting phenomenon given that the IGF-IR’s major effect on the cell 
cycle is not primarily exerted in G2/M, but in the G1/S transition.  IGF-IR regulates 
the G1/S transition by activation of PI-3K/Akt and/or ERK pathways, which leads to 
Cyclin D1 and CDK4 expression and cell cycle progression (Lavoie, L'Allemain, 
Brunet, Muller, & Pouyssegur, 1996). IGF-IR may also regulate the G2/M transition 
by upregulation of Cyclins A and B, and cdc2 synthesis, but this function is not as 
well documented (Furlanetto, Harwell, & Frick, 1994). 
Concomitant with G2/M cell cycle arrest, PPP treatment of 231Br and BT474 
Br3 cells potently blocked the activation of molecules downstream of IGF-IR in a 
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dose-dependent manner, in particular the phosphorylation of AKT-Ser473 and 
p70S6 kinase-Thr389 (Figure 23).  It is unlikely that inhibition of AKT 
phosphorylation by PPP is responsible for the G2/M cell cycle arrest we observed, 
since AKT is primarily involved in the G1/S transition. It is possible that the G2/M 
cell cycle arrest resulted in less cycling cells and therefore a decrease in overall 
AKT activation.  Another explanation could be off-target effects of PPP treatment, 
such as inhibition of the EGFR or c-Met receptors, which are both known to play a 
role in the G2/M transition (Baker & Yu, 2001) (Factor et al., 2010).  Further studies 
should address whether PPP-induced G2/M arrest and AKT pathway 
downregulation are linked, or a result of off-target effects in our cell lines. 
In addition, PPP inhibited biological functions of the 231 brain-seeking cells in 
which PPP-treated cells had impaired migration (Figure 24A, quantitation shown in 
Figure 24B) and invasion (Figure 24C, quantitation shown in Figure 24D).  PPP did 
not significantly inhibit the migration or invasion of BT474 Br3 cells (Figure 24E), 
which may be due to the low baseline in vitro metastatic properties of this luminal-
type cell line.  Perhaps overexpression of IGF-IR in BT474 M1 (parental) or BT474 
Br3 cells combined with PPP inhibitor experiments using IGF-1 as a 
chemoattractant would better address the significance of IGF-IR in these less 
aggressive, yet still brain-seeking, breast cancer cells.  Furthermore, treatment of 
231 Parental and brain-seeking breast cancer cells with different concentrations of 
PPP inhibited wound-healing (Figure 25A) and cell proliferation (Figure 25B), and 
these effects were more pronounced in the brain-seeking cells that overexpress 
IGF-IR.  Thus, PPP inhibits cell migration and proliferation while enhancing cell-cell 
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adhesion, similar to the effects achieved by siRNA and shRNA ablation of IGF-IR.  
Taken together, these data indicate that IGF-IR-driven signaling could be potentially 
targeted by PPP in highly invasive brain-seeking cells.  Further studies should test 
this hypothesis in a mouse model of experimental brain metastasis.
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Figure 22 
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Figure 22. Picropodophyllin induces G2/M cell cycle arrest in brain-seeking 
breast cancer cells. 
 
Cell cycle analysis by propidium iodide staining of brain-seeking cells (231Br and 
BT474 Br3) treated with 1 µg/mL PPP for 48 hr.  
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Figure 23 
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Figure 23. Picropodophyllin inhibits activation of IGF-IR downstream targets 
in brain-seeking breast cancer cells. 
Immunoblot of phospho-proteins activation downstream of IGF-IR in brain-seeking 
cells treated with escalating concentrations of PPP for 24h. 
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Figure 24 
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Figure 24. Picropodophyllin inhibits migration and invasion in 231 brain-
seeking breast cancer cells.  
A, Transwell migration assay of 231Br cells treated with 1 µg/mL PPP for 24 hr.   
B, Quantitative analysis of relative number of migrating cells from (A).   
C, Matrigel invasion assay of 231Br cells treated with 1 µg/mL PPP for 24 hr.   
D, Quantitative analysis of relative number of migrating cells from (D).  
All migration and invasion assays used complete medium as a chemoattractant. 
Images shown are representative of one of three experiments performed.  Bars 
represent mean ± SEM. 
E, Transwell migration and matrigel invasion assay of BT474 Br3 cells. 
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Figure 25 
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Figure 25. Picropodophyllin inhibits wound healing and proliferation in brain-
seeking breast cancer cells. 
 
A, Wound healing assay of parental and brain-seeking 231 cells treated with 
different concentrations of PPP.  Brain-seeking cells have decreased wound healing 
ability in response to PPP. 
 
B, MTT assay of cells treated with PPP for 48 hours.  Proliferation of brain-seeking 
cells is more sensitive to PPP treatment than parental cells. 
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CHAPTER 5 
 
SUMMARY AND DISCUSSION 
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5.1 Summary 
 The work described in this thesis is summarized in the model depicted in 
Figure 32.  In brief, the IGF-IR signaling axis was activated both endogenously and 
in an IGF-1 dependent manner in brain-seeking subclones of breast cancer cell 
lines.  IGF-IR activation is determined by the level of total tyrosine phosphorylation 
of the IGF-I receptor, and by the phosphorylation of specific tyrosine residues 1131 
and 1135, which pertain to the kinase domain.  IGF-IR activation was also evident 
by the tyrosine phosphorylation detected in IRS-2, the scaffold protein immediately 
downstream of IGF-IR that is known to activate migratory and invasive functions in 
metastatic breast cancer cells.  AKT, but not ERK, was also phosphorylated both 
endogenously and upon IGF-1 stimulation of brain-seeking cells.  We found that 
IGF-IR activation was at least partially dependent on IGFBP3 protein, which is 
highly secreted in 231Br cells but not in parental 231 cells.  IGFBP3 knockdown 
resulted in significant downregulation of IGF-IR tyrosine phosphorylation. 
When we experimentally ablated IGF-IR protein in brain-seeking cells, either by 
transient siRNA transfection or stable shRNA transfection, we observed a decrease 
in the proliferation, motility and invasiveness of cells.  When injected into the 
intracarotid artery of nude mice, these IGF-IR shRNA knockdown cells displayed a 
delay in their colonization of the brain, which led to a significantly longer lifespan of 
these mice that acquired brain metastases.  The IHC staining confirmed that IGF-IR 
expression was high in the control brain-seeking cells, but interestingly the brain 
metastases formed from shRNA groups had retained or partially re-expressed IGF-
IR, although lower than the control groups.  IGF-IR shRNA effects on mammary fat 
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pad tumor growth did not behave as expected, with one knockdown group 
completely unable to form tumors and the other producing equal tumor volumes as 
the control groups. The IGF-IR inhibitor PPP caused G2/M cell cycle arrest as well 
as dose-dependent downregulation of AKT phosphorylation and p70S6Kinase. 
In a separate study aimed at better characterize the AKT activation profile 
between brain-seeking and parental breast cancer cells, we found that AKT is 
constitutively phosphorylated in the nucleus of brain-seeking cells, and this 
phosphorylated form is stimulated by the IGF-IR signaling axis.  Nuclear phospho-
AKT was enhanced upon IGF-1 stimulation and downregulated in IGF-IR shRNA 
knockdown cell lines.  However, when stimulated with EGF-ligand or treated with 
the EGFR inhibitor Tarceva, nuclear phospho-AKT remained unchanged.  
Furthermore, we found that transient transfection with a combination of AKT1 and 
AKT3 are the two major isoforms of AKT that are phosphorylated in the nucleus of 
brain-seeking cells. 
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Figure 26 
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5.2 Discussion 
An important step in the development of rational therapies for brain-metastatic 
breast cancer is the identification of major molecular drivers of the disease. The 
study presented here supports the notion that (A) the IGF-IR signaling axis is active 
and mediates malignant phenotypes in brain-seeking breast cancer cells, (B) both 
genetic and pharmacological inhibition IGF-IR decrease the malignancy of brain-
seeking cells in vitro, and remarkably (C) IGF-IR shRNA-expressing breast cancer 
cells have a decreased ability to form brain tumors in an in vivo model of 
experimental brain metastasis. The studies presented here support that IGF-IR 
signaling is a driver of brain metastases, with important implications in which 
therapeutic inhibition of this receptor may prevent or delay the establishment of IGF-
IR-positive metastatic brain tumors from breast cancer. 
 In our model system, 231Br and BT474Br3 cells expressed more of the 
autophosphorylated form of IGF-IR.  This result is in agreement with previous 
studies that found activated phospho-IGF-IR/IR and phospho-S6K are associated 
with poor survival in patients with invasive breast cancer (Law et al., 2008).  
Furthermore, phospho-IGF-IR and phospho-AKT were recently shown to correlate 
with metastases of breast cancer to the brain in a cohort of 42 brain metastases 
from breast and lung cancer patients (Improta et al., 2011).  In our study, we found 
constitutively activated IGF-I Receptor when cells were examined in normal serum 
conditions (10%FBS/DMEM), concomitant with a baseline AKT phosphorylation at 
Ser473, suggesting constitutive IGF-IR pathway activation (Figs. 5A, 5B, 12, 26).  
This constitutive IGF-IR activation was abrogated when we eliminated the IGF-I 
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Receptor through siRNA, shRNA, or by treatment with PPP (Figs. 11-14, 22-25).  
Indeed, phosphorylated IGF-IR appears to be a recurrent theme in advanced breast 
cancers, and our results further elucidated its biological significance. 
 We concluded that constitutive autophosphorylation of IGF-IR is likely due to 
regulation by the autocrine components of the IGF-IR signaling axis, such as IGF-1 
and IGFBP3.  IGFBP3 was overexpressed in 231Br brain-seeking cells, and its 
knockdown by siRNA resulted in a significant decrease of IGF-IR Tyr 
phosphorylation. These findings led us to believe that IGFBP3 may enhance IGF-1 
bioavailability and subsequently activate IGF-IR in our model system.  Various 
studies suggest mechanisms of IGF-IR induction by IGFBP3, including signaling 
through sphingosine kinase (Sphk) and cross-activation of IGF-IR and EGFR and 
binding of IGFBP3 (Martin et al., 2009). However, further work is needed to confirm 
the IGF-1 ligand-dependent function of IGFBP3 on IGF-IR. 
 To address the biological significance of IGF-IR, we constructed brain-seeking 
231 cells stably expressing IGF-IR shRNA. Ablation of IGF-IR diminished the 
proliferation, migration, and invasion of 231Br cells in vitro. Knocking down IGF-IR 
delayed the outgrowth of brain metastases and extended the survival of mice 
bearing brain metastases. When we examined the brains of mice bearing brain 
metastases of shIGF-IR 231Br cells, we were surprised to find that these 
metastases expressed IGF-IR, albeit at lower levels than the brain metastases from 
the vector 231Br group. We speculate that in our model, the brain microenvironment 
selected for, if not promoted, the survival of tumor cells with remaining expression of 
IGF-IR.   
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5.2.I Implications for brain metastasis in Her2+ and triple negative breast 
cancer 
 The cause of brain metastasis remains elusive although 25 to 40% of patients 
with Her2+ and triple-negative breast cancer (TNBC) have a significantly increased 
likelihood of developing brain metastases (Duchnowska et al., 2012; Steeg et al., 
2011) (Hicks et al., 2006). Interestingly, the increased signaling of the IGF-IR has 
been shown to associate with resistance of Her2+ breast cancers to trastuzumab 
(Gallardo et al., 2012).  A recent preclinical study showed the expression of an IGF-
IR gene signature in TNBC that consequently sensitizes this cancer subtype to anti-
IGF-IR therapy (Litzenburger et al., 2011). IGF-IR signaling was also shown to 
promote the proliferation and survival of TNBC cells, and it was associated with 
early tumor recurrence in TNBC patients when accompanied by PTEN loss 
(Davison, de Blacquiere, Westley, & May, 2011; Iqbal, Thike, Cheok, Tse, & Tan, 
2012). In addition, other groups have also suggested the reliance of TNBC cell lines 
on IGF-1 signaling (Davison et al., 2011).  It is worth noting that the 231Br cell line 
used in our model system is a TNBC cell line, and our results support the notion 
that IGF-IR might play a role in brain metastasis of TNBC. Future studies with 
additional TNBC models should explore the role of IGF-IR in this aggressive subset 
of breast cancers in further detail.   
 
5.2.II Implications for pharmacological targeting of the IGF-IR signaling axis 
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 We found that PPP potently inhibited IGF-IR signaling in breast cancer cells in 
vitro.  A previous report identified that the major IGF-regulated process in the cell 
cycle is upregulation of genes involved in the G2/M transition (Litzenburger et al., 
2011). Our findings confirmed that the same holds true in brain-seeking breast 
cancer cells. Furthermore, in an intracranial xenograft model of glioblastoma, PPP 
demonstrated ability to cross the blood-brain-barrier and cause tumor regression as 
well as downregulation of p-AKT, suggesting its potential usefulness in brain 
metastasis treatment (Yin et al., 2010). However, a recent study of drug delivery in 
mouse models of breast cancer brain metastasis found the heterogeneity of blood-
tumor-barrier permeability to be a major obstacle to drug efficacy, and further 
validation of PPP in these mouse models is needed (Lockman et al., 2010). To our 
knowledge, this is the first study to establish a clear biological role of the IGF-IR and 
its activation in brain-specific metastases of breast cancer, suggesting that 
dysregulated molecules along the IGF-IR signaling pathway play a significant role in 
the establishment of brain metastasis. Further studies should pursue the utility of 
IGF-IR inhibitors for the prevention and treatment of brain metastases of breast 
cancer, particularly in a setting where the patient is refractory to other therapies. 
 
5.2.III Implications of using human breast cancer cell lines in models of brain 
metastasis 
Our model of experimental brain metastasis consisted of injection of human breast 
cancer cell lines that had been selected in vitro for their brain-seeking properties.  
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Our model, therefore, may not be the best for studies of spontaneous brain 
metastasis, or to study the early steps of brain metastasis when tumor cells leave 
their primary and/or metastatic tumor site and the characteristics that attract these 
cells to the brain as a metastatic site.  Injection of the tumor cells into the carotid 
artery of mice circumvents all of these early steps, and even the major anatomical 
barrier of the lung that tumor cells encounter prior to reaching the brain.  Therefore, 
it is important to note that our model primarily deals with the effect of IGF-IR 
knockdown in the ability of breast cancer cells to arrest and attach to the capillary 
bed of the brain, cross the blood-brain-barrier, survive in the brain to establish 
metastases and eventually cause morbidity due to tumor burden.  Future studies 
should fine-tune exactly which of these later steps of metastasis the IGF-IR is 
involved in.  For example, in vitro transendothelial migration assays using human 
brain microvascular endothelial cells using IGF-1 as a chemoattractant would 
provide clues about brain-derived IGF-1’s role in inducing breast cancer cells to 
cross the blood-brain barrier, much like SDF-1 acts on the cell surface receptor 
CXCR4.  Co-culture studies of astrocytes and our IGF-IR-knockdown breast cancer 
cells would yield more information about the crosstalk between breast cancer cells 
with cells of the brain parenchyma in the activation of survival cues. 
5.2.IV Implications of using epithelial vs. mesenchymal cell types in modeling 
brain metastasis.   
The MDA-MB-231 breast cancer cell line is a highly malignant and metstatic breast 
cancer cell line from epithelial origin.  Despite its epithelial origin, the 231 cell line 
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behaves like an undifferentiated, mesenchymal cell type and in gene expression 
profiling studies it was found to express mostly mesenchymal genes (Charafe-
Jauffret et al., 2006).  This is in contrast to the BT-474 cell line that is also from 
epithelial origin but is more differentiated and has been classified into the luminal 
subtype.  Luminal cell types are believed to be less invasive than mesenchymal or 
basal types due to the expression of the cell-fate differentiating factor GATA-3 
(Asselin-Labat et al., 2007), although recent evidence suggests that luminal cell 
types also possess the ability to initiate metastatic tumors (Kim et al., 2012).  It is 
important to note the difference in intrinsic behaviors between the 231 and BT-474 
cell lines, because this may explain the differences we observed between the two 
cell types in in vitro experiments in our model of brain metastasis.  In Figure 24, for 
instance, the migratory and invasive behavior of the 231Br cell line was inhibited by 
treatment with the IGF-IR inhibitor PPP, while the migration of BT474 Br3 cells was 
unchanged, and invasion was not as pronounced as in 231Br cells.  Due to its non-
invasive phenotype, the baseline metastatic potential of BT474 Br 3 cells is already 
very low, which presents a challenge in experiments where a decreased metastatic 
potential is expected.  A more appropriate experiment for this cell type may be to 
measure the increase in in vitro metastatic potential under exogenous 
overexpression of IGF-IR. 
5.2.V  Role of EMT/MET and the brain microenvironment 
Epithelial-to-mesenchymal transition (EMT) is the process by which tumor cells 
originating in the epithelium degrade the extracellular matrix and separate from the 
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tumor to become undifferentiated, mesenchymal-like cells with enhanced invasive 
and metastatic ability (Gao, Vahdat, Wong, Chang, & Mittal, 2012; Kalluri & 
Weinberg, 2009). 
It was recently shown that mesenchymal-like 231 breast cancer cells can revert to 
the epithelial phenotype in the metastatic organ microenvironment in a process 
called MErT, or mesenchymal to epithelial reverting transition (Y. L. Chao, Shepard, 
& Wells, 2010). MErT was achieved by re-expression of E-cadherin in the 
metastatic tumor microenvironment, through a loss of methylation of the E-cadherin 
promoter.  It would be of interest to perform IHC studies of brain metastases arising 
from 231Br cells, to test whether the brain microenvironment indeed induces the re-
expression of E-cadherin in these cells, and whether IGF-IR has any part in this 
process.  Since IGF-IR knockdown reduced brain metastasis in our model system, it 
would further strengthen our hypothesis that IGF-IR provides a survival advantage if 
somehow as a result of IGF-IR knockdown, E-cadherin re-expression was inhibited 
as well.  Previous studies have found that IGF-IR overexpression in breast cancer 
cells promotes E-cadherin dependent cell-cell adhesion, cellular aggregation and 
survival (Guvakova & Surmacz, 1997).  Also, IGF-IR knockdown in breast cancer 
cells resulted in a decrease of E-cadherin expression and destabilization of the E-
cadherin-catenin complex, which is responsible for epithelial cell-cell adhesion and 
maintenance of the tumor architecture (Pennisi, Barr, Nunez, Stannard, & Le Roith, 
2002; Wijnhoven, Dinjens, & Pignatelli, 2000). 
5.3 Future Studies 
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This dissertation deals primarily with characterization of the intrinsic metastatic 
properties of brain-seeking breast cancer cells, the autocrine signaling that 
enhances metastatic properties, and the role of IGF-IR expression in the later 
stages of the metastatic process in vivo.  Future studies should address the 
interactions between IGF-IR expressing breast cancer cells and other cell types in 
the brain microenvironment, such as vascular endothelial cells, astrocytes, and 
pericytes.  The role of brain-derived IGF-1 and IGFBP3 in the promotion of 
metastatic cell survival is also of interest, as is the effect of breast cancer cells’ 
intrinsic IGFBP3 overexpression in modulation of the brain parenchyma.   
It is known that breast cancer patients differentially express IGF-1 and IGFBP3 
in the circulation, but the relevance of their expression levels and their contribution 
to metastasis is still unknown.  Therefore, the effect of circulating IGF-1 and 
IGFBP3 levels on the outcome of brain metastases of IGF-IR-positive breast 
cancers should be a subject for future studies. 
We show that PPP successfully induced G2/M cell cycle arrest in both, 231Br 
and BT474 Br3 cells.  As a next step, in vivo studies should examine the efficacy of 
PPP in preventing or reducing brain metastases at different doses, in order to 
establish whether inhibition of IGF-IR would be a good target to pursue in further 
pre-clinical studies.  
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CHAPTER 6 
 
APPENDIX: 
NUCLEAR AKT IN BRAIN SEEKING 
BREAST CANCER CELLS 
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6.1 Nuclear AKT signaling  
Activated AKT has been previously shown to localize in the nucleus of cancer 
cells and correlates with poor progression in several cancers.  In myocardial cells, 
for example, targeting of AKT to the nucleus resulted in enhanced cell survival and 
increased kinase activity (Shiraishi et al., 2004).  Furthermore, myocardial epithelial 
cells that overexpress IGF-IR have an enrichment of nuclear phospho-AKT Ser47, 
which is also associated with enhanced cell survival (Camper-Kirby et al., 2001).   
We previously observed that AKT signaling is stimulated by IGF-IR signaling in 
our model system (Figures 7 and 12).  When we looked at the subcellular activation 
profile of AKT, we were surprised to find that AKT was constitutively phosphorylated 
in the nucleus of 231Br cells (Figure 26).  Importantly, nuclear phospho-AKT 
observed most likely has active kinase function, since we also detected enhanced 
endogenous phosphorylation of AKT nuclear substrates, compared to 231 parental 
cells which did not express nuclear phospho-AKT (Figure 26).  Furthermore, AKT 
phosphorylation was further enhanced by stimulation with IGF-1 ligand, which 
suggests that constitutive IGF-IR signaling may be at least partially responsible for 
enhanced nuclear AKT signaling. 
 In order to test the hypothesis that IGF-IR increases nuclear AKT signaling, we 
obtained nuclear lysates from the 231Br-Vector, 231Br-shIGF-IR (B) and 231Br-
shIGF-IR (F) cell lines.  231Br Vector cells had Ser473 and Thr307 AKT 
phosphorylation, as expected. Ser473 phosphorylation was unaffected by IGF-IR 
knockdown in the shIGFR cells, however, AKT phosphorylation at Thr308 was 
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downregulated.  The phosphorylation of nuclear AKT ser/thr substrates at the 
RXXS/T motif was also partially downregulated in the IGF-IR knockdown cell lines, 
although not dramatically, perhaps due to the residual Ser473 phosphorylation. 
 Next, we were interested in discerning which of the three AKT isoforms is 
phosphorylated in the nucleus of 231Br cells. We transiently transfected 231Br cells 
with control siRNA, or siRNAs targeting a combination of two or three AKT isoforms.  
We then isolated nuclear lysates from siRNA-transfected cells, and assessed the 
resulting AKT phosphorylation.  AKT1 and AKT3 knockdown contributed the most 
significant decrease in phospho-AKT at both Ser473 and Thr308.  This is an 
important result since both AKT1 and AKT3, have been implicated in metastasis 
and/or in vitro metastatic properties.  In thyroid cancer, for example, it was shown 
that AKT1 and activated AKT co-localize in the nucleus of malignant cells, but not 
normal thyroid cells, and correlates with increased malignancy and migration 
(Vasko et al., 2004).  Interestingly, it was also shown that an AKT1 mutant lacking a 
nuclear export sequence is sufficient to cause increased in vitro migration of Akt1 -/- 
fibroblasts (Saji et al., 2005).  Akt3 deregulation was found to correlate with 
melanoma malignancy, and AKT3 expression progressively increases in more 
advanced stages of metastasis (Stahl et al., 2004).  Taken together, our data 
suggest that IGF-IR signaling axis activation in brain-seeking breast cancer cells 
may lead to an enrichment of phosphorylated and kinase-active nuclear AKT, 
primarily AKT1 and AKT3, which then may activate nuclear substrates that promote 
migration and metastasis.  Further studies should validate specific targets enhanced 
by this signaling axis, and further clarify the functional significance of nuclear AKT in 
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vivo.
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Figure 27 
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Figure 27. Nuclear localization of phospho-AKT and enhanced AKT nuclear 
substrate activation in brain-seeking breast cancer cells 
 
Lysates of cytosolic and nuclear compartments of 231 and 231Br cells were 
obtained.  Cytosolic fraction on the left is confirmed by Tubulin expression, and 
purity of the nuclear fraction on the right is confirmed by Lamin-B expression.  
Nuclear phospho-AKT is found in 231Br cells, but not parental cells. Constitutive 
AKT kinase activation is confirmed by serine/threonine phosphorylation of AKT 
substrates on the RXXS/T motif.  Nuclear AKT and nuclear AKT substrate Ser/Thr 
phosphorylation are further stimulated by IGF-1 ligand. 
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Figure 28 
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Figure 28. Nuclear phospho-AKT and nuclear substrate activation are 
downregulated in IGF-IR knockdown brain-seeking breast cancer cells 
 
Lysates of cytosolic and nuclear compartments of 231Br-Vector, 231Br-shIGF-IR 
(B) and 231Br-shIGF-IR (F) were obtained.  Nuclear AKT phosphorylation at Ser473 
is found in 231Br Vector cells and unaffected by IGF-IR knockdown.  AKT 
phosphorylation at Thr308 is downregulated in IGF-IR knockdown cells.  
Phosphorylation of nuclear AKT serine/threonine substrates on the RXXS/T motif is 
partially downregulated in the IGF-IR knockdown cell lines. 
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Figure 29 
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Figure 29. Nuclear phospho-AKT signal observed is primarily from AKT1 and 
AKT3 isoforms. 
 
231Br cells were transiently transfected with control siRNA, or siRNAs targeting a 
combination of two or three AKT isoforms.  Nuclear lysates from siRNA-transfected 
cells were isolated, and AKT phosphorylation was assessed.  AKT1 and AKT3 
knockdown contributed the most significant decrease in phospho-AKT at both 
Ser473 and Thr308. 
 
	  126	  
 
 
 
 
 
CHAPTER 7 
 
REFERENCES 
 
 
 
 
	  127	  
Abramovitch, S., Glaser, T., Ouchi, T., & Werner, H. (2003). BRCA1-Sp1 
interactions in transcriptional regulation of the IGF-IR gene. [Research 
Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, P.H.S.]. FEBS Lett, 541(1-3), 149-154.  
Adelaide, J., Finetti, P., Bekhouche, I., Repellini, L., Geneix, J., Sircoulomb, F., . . . 
Chaffanet, M. (2007). Integrated profiling of basal and luminal breast 
cancers. [Research Support, Non-U.S. Gov't]. Cancer Res, 67(24), 11565-
11575. doi: 10.1158/0008-5472.CAN-07-2536 
Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., 
Schell, M. C., . . . Curran, W. J., Jr. (2004). Whole brain radiation therapy 
with or without stereotactic radiosurgery boost for patients with one to three 
brain metastases: phase III results of the RTOG 9508 randomised trial. 
[Clinical Trial 
Clinical Trial, Phase III 
Multicenter Study 
Randomized Controlled Trial 
Research Support, U.S. Gov't, P.H.S.]. Lancet, 363(9422), 1665-1672. doi: 
10.1016/S0140-6736(04)16250-8 
Asselin-Labat, M. L., Sutherland, K. D., Barker, H., Thomas, R., Shackleton, M., 
Forrest, N. C., . . . Visvader, J. E. (2007). Gata-3 is an essential regulator of 
	  128	  
mammary-gland morphogenesis and luminal-cell differentiation. [Research 
Support, Non-U.S. Gov't]. Nat Cell Biol, 9(2), 201-209. doi: 10.1038/ncb1530 
Bachelot, T., Romieu, G., Campone, M., Dieras, V., Cropet, C., Dalenc, F., . . . 
Labbe-Devilliers, C. (2013). Lapatinib plus capecitabine in patients with 
previously untreated brain metastases from HER2-positive metastatic breast 
cancer (LANDSCAPE): a single-group phase 2 study. [Research Support, 
Non-U.S. Gov't]. Lancet Oncol, 14(1), 64-71. doi: 10.1016/S1470-
2045(12)70432-1 
Baker, N. E., & Yu, S. Y. (2001). The EGF receptor defines domains of cell cycle 
progression and survival to regulate cell number in the developing Drosophila 
eye. [Research Support, U.S. Gov't, P.H.S.]. Cell, 104(5), 699-708.  
Barnholtz-Sloan, J. S., Sloan, A. E., Davis, F. G., Vigneau, F. D., Lai, P., & Sawaya, 
R. E. (2004). Incidence proportions of brain metastases in patients 
diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance 
System. [Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, P.H.S.]. J Clin Oncol, 22(14), 2865-2872. doi: 
10.1200/JCO.2004.12.149 
Bos, P. D., Zhang, X. H., Nadal, C., Shu, W., Gomis, R. R., Nguyen, D. X., . . . 
Massague, J. (2009). Genes that mediate breast cancer metastasis to the 
brain. [Research Support, N.I.H., Extramural 
	  129	  
Research Support, Non-U.S. Gov't]. Nature, 459(7249), 1005-1009. doi: 
10.1038/nature08021 
Buijs, J. T., Stayrook, K. R., & Guise, T. A. (2011). TGF-beta in the Bone 
Microenvironment: Role in Breast Cancer Metastases. Cancer Microenviron, 
4(3), 261-281. doi: 10.1007/s12307-011-0075-6 
Camper-Kirby, D., Welch, S., Walker, A., Shiraishi, I., Setchell, K. D., Schaefer, E., . 
. . Sussman, M. A. (2001). Myocardial Akt activation and gender: increased 
nuclear activity in females versus males. [Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, P.H.S.]. Circ Res, 88(10), 1020-1027.  
Carbonell, W. S., Ansorge, O., Sibson, N., & Muschel, R. (2009). The vascular 
basement membrane as "soil" in brain metastasis. [Research Support, N.I.H., 
Extramural 
Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, Non-P.H.S.]. PLoS One, 4(6), e5857. doi: 
10.1371/journal.pone.0005857 
Chaffer, C. L., Brennan, J. P., Slavin, J. L., Blick, T., Thompson, E. W., & Williams, 
E. D. (2006). Mesenchymal-to-epithelial transition facilitates bladder cancer 
metastasis: role of fibroblast growth factor receptor-2. [Research Support, 
Non-U.S. Gov't 
	  130	  
Research Support, U.S. Gov't, Non-P.H.S.]. Cancer Res, 66(23), 11271-11278. doi: 
10.1158/0008-5472.CAN-06-2044 
Chao, Y., Wu, Q., Acquafondata, M., Dhir, R., & Wells, A. (2012). Partial 
mesenchymal to epithelial reverting transition in breast and prostate cancer 
metastases. Cancer Microenviron, 5(1), 19-28. doi: 10.1007/s12307-011-
0085-4 
Chao, Y. L., Shepard, C. R., & Wells, A. (2010). Breast carcinoma cells re-express 
E-cadherin during mesenchymal to epithelial reverting transition. [Research 
Support, U.S. Gov't, Non-P.H.S.]. Mol Cancer, 9, 179. doi: 10.1186/1476-
4598-9-179 
Charafe-Jauffret, E., Ginestier, C., Monville, F., Finetti, P., Adelaide, J., Cervera, N., 
. . . Bertucci, F. (2006). Gene expression profiling of breast cell lines 
identifies potential new basal markers. [Comparative Study 
Research Support, Non-U.S. Gov't]. Oncogene, 25(15), 2273-2284. doi: 
10.1038/sj.onc.1209254 
Cheng, X., & Hung, M. C. (2007). Breast cancer brain metastases. [Research 
Support, N.I.H., Extramural 
Research Support, U.S. Gov't, Non-P.H.S. 
Review]. Cancer Metastasis Rev, 26(3-4), 635-643. doi: 10.1007/s10555-007-9083-
x 
	  131	  
Chitnis, M. M., Yuen, J. S., Protheroe, A. S., Pollak, M., & Macaulay, V. M. (2008). 
The type 1 insulin-like growth factor receptor pathway. [Research Support, 
Non-U.S. Gov't 
Review]. Clin Cancer Res, 14(20), 6364-6370. doi: 10.1158/1078-0432.CCR-07-
4879 
Davison, Z., de Blacquiere, G. E., Westley, B. R., & May, F. E. (2011). Insulin-like 
growth factor-dependent proliferation and survival of triple-negative breast 
cancer cells: implications for therapy. [Research Support, Non-U.S. Gov't]. 
Neoplasia, 13(6), 504-515.  
Duchnowska, R., Biernat, W., Szostakiewicz, B., Sperinde, J., Piette, F., Haddad, 
M., . . . Jassem, J. (2012). Correlation between quantitative HER-2 protein 
expression and risk for brain metastases in HER-2+ advanced breast cancer 
patients receiving trastuzumab-containing therapy. Oncologist, 17(1), 26-35. 
doi: 10.1634/theoncologist.2011-0212 
Dyer, M. A., Kelly, P. J., Chen, Y. H., Pinnell, N. E., Claus, E. B., Lee, E. Q., . . . 
Alexander, B. M. (2012). Importance of extracranial disease status and tumor 
subtype for patients undergoing radiosurgery for breast cancer brain 
metastases. Int J Radiat Oncol Biol Phys, 83(4), e479-486. doi: 
10.1016/j.ijrobp.2012.01.054 
	  132	  
Eichler, A. F., Chung, E., Kodack, D. P., Loeffler, J. S., Fukumura, D., & Jain, R. K. 
(2011). The biology of brain metastases-translation to new therapies. 
[Research Support, N.I.H., Extramural 
Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, Non-P.H.S. 
Review]. Nat Rev Clin Oncol, 8(6), 344-356. doi: 10.1038/nrclinonc.2011.58 
Factor, V. M., Seo, D., Ishikawa, T., Kaposi-Novak, P., Marquardt, J. U., Andersen, 
J. B., . . . Thorgeirsson, S. S. (2010). Loss of c-Met disrupts gene expression 
program required for G2/M progression during liver regeneration in mice. 
[Research Support, N.I.H., Intramural]. PLoS One, 5(9). doi: 
10.1371/journal.pone.0012739 
Fernandez, A. M., & Torres-Aleman, I. (2012). The many faces of insulin-like 
peptide signalling in the brain. [Review]. Nat Rev Neurosci, 13(4), 225-239. 
doi: 10.1038/nrn3209 
Firth, S. M., & Baxter, R. C. (1999). Characterisation of recombinant glycosylation 
variants of insulin-like growth factor binding protein-3. [Research Support, 
Non-U.S. Gov't]. J Endocrinol, 160(3), 379-387.  
Firth, S. M., & Baxter, R. C. (2002). Cellular actions of the insulin-like growth factor 
binding proteins. [Review]. Endocr Rev, 23(6), 824-854.  
	  133	  
Fitzgerald, D. P., Subramanian, P., Deshpande, M., Graves, C., Gordon, I., Qian, 
Y., . . . Steeg, P. S. (2012). Opposing effects of pigment epithelium-derived 
factor on breast cancer cell versus neuronal survival: implication for brain 
metastasis and metastasis-induced brain damage. [Research Support, 
N.I.H., Intramural 
Research Support, U.S. Gov't, Non-P.H.S.]. Cancer Res, 72(1), 144-153. doi: 
10.1158/0008-5472.CAN-11-1904 
Fujita-Yamaguchi, Y., LeBon, T. R., Tsubokawa, M., Henzel, W., Kathuria, S., 
Koyal, D., & Ramachandran, J. (1986). Comparison of insulin-like growth 
factor I receptor and insulin receptor purified from human placental 
membranes. [Comparative Study 
Research Support, U.S. Gov't, P.H.S.]. J Biol Chem, 261(35), 16727-16731.  
Furlanetto, R. W., Harwell, S. E., & Frick, K. K. (1994). Insulin-like growth factor-I 
induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro. 
[Research Support, U.S. Gov't, P.H.S.]. Mol Endocrinol, 8(4), 510-517.  
Gallardo, A., Lerma, E., Escuin, D., Tibau, A., Munoz, J., Ojeda, B., . . . Peiro, G. 
(2012). Increased signalling of EGFR and IGF1R, and deregulation of 
PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 
breast carcinomas. [Research Support, Non-U.S. Gov't]. Br J Cancer, 106(8), 
1367-1373. doi: 10.1038/bjc.2012.85 
	  134	  
Gao, D., Vahdat, L. T., Wong, S., Chang, J. C., & Mittal, V. (2012). 
Microenvironmental regulation of epithelial-mesenchymal transitions in 
cancer. [Research Support, N.I.H., Extramural 
Review]. Cancer Res, 72(19), 4883-4889. doi: 10.1158/0008-5472.CAN-12-1223 
Gibson, S. L., Ma, Z., & Shaw, L. M. (2007). Divergent roles for IRS-1 and IRS-2 in 
breast cancer metastasis. [Comparative Study 
Research Support, N.I.H., Extramural 
Review]. Cell Cycle, 6(6), 631-637.  
Girnita, A., Girnita, L., del Prete, F., Bartolazzi, A., Larsson, O., & Axelson, M. 
(2004). Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor 
and malignant cell growth. [Research Support, Non-U.S. Gov't]. Cancer Res, 
64(1), 236-242.  
Gombos, A., Metzger-Filho, O., Dal Lago, L., & Awada-Hussein, A. (2012). Clinical 
development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at 
the crossroad? Invest New Drugs, 30(6), 2433-2442. doi: 10.1007/s10637-
012-9811-0 
Grkovic, S., O'Reilly, V. C., Han, S., Hong, M., Baxter, R. C., & Firth, S. M. (2012). 
IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of 
breast cancer cells exposed to adverse microenvironments. Oncogene. doi: 
10.1038/onc.2012.264 
	  135	  
Guvakova, M. A., & Surmacz, E. (1997). Overexpressed IGF-I receptors reduce 
estrogen growth requirements, enhance survival, and promote E-cadherin-
mediated cell-cell adhesion in human breast cancer cells. [Research 
Support, U.S. Gov't, Non-P.H.S. 
Research Support, U.S. Gov't, P.H.S.]. Exp Cell Res, 231(1), 149-162. doi: 
10.1006/excr.1996.3457 
Hanafusa, T., Shinji, T., Shiraha, H., Nouso, K., Iwasaki, Y., Yumoto, E., . . . Koide, 
N. (2005). Functional promoter upstream p53 regulatory sequence of 
IGFBP3 that is silenced by tumor specific methylation. [Research Support, 
Non-U.S. Gov't]. BMC Cancer, 5, 9. doi: 10.1186/1471-2407-5-9 
Hicks, D. G., Short, S. M., Prescott, N. L., Tarr, S. M., Coleman, K. A., Yoder, B. J., 
. . . Weil, R. J. (2006). Breast cancers with brain metastases are more likely 
to be estrogen receptor negative, express the basal cytokeratin CK5/6, and 
overexpress HER2 or EGFR. [Research Support, Non-U.S. Gov't]. Am J 
Surg Pathol, 30(9), 1097-1104. doi: 10.1097/01.pas.0000213306.05811.b9 
Hiraga, T., Myoui, A., Hashimoto, N., Sasaki, A., Hata, K., Morita, Y., . . . Yoneda, T. 
(2012). Bone-derived IGF mediates crosstalk between bone and breast 
cancer cells in bony metastases. Cancer Res. doi: 10.1158/0008-5472.CAN-
11-3061 
Improta, G., Zupa, A., Fillmore, H., Deng, J., Aieta, M., Musto, P., . . . Wulfkuhle, J. 
D. (2011). Protein pathway activation mapping of brain metastasis from lung 
	  136	  
and breast cancers reveals organ type specific drug target activation. 
[Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, P.H.S.]. J Proteome Res, 10(7), 3089-3097. doi: 
10.1021/pr200065t 
Iqbal, J., Thike, A. A., Cheok, P. Y., Tse, G. M., & Tan, P. H. (2012). Insulin growth 
factor receptor-1 expression and loss of PTEN protein predict early 
recurrence in triple-negative breast cancer. Histopathology. doi: 
10.1111/j.1365-2559.2012.04255.x 
Jackson, J. G., Zhang, X., Yoneda, T., & Yee, D. (2001). Regulation of breast 
cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic 
variants of human breast cancer cell lines. [Research Support, U.S. Gov't, 
P.H.S.]. Oncogene, 20(50), 7318-7325. doi: 10.1038/sj.onc.1204920 
Joyce, J. A., & Pollard, J. W. (2009). Microenvironmental regulation of metastasis. 
[Research Support, N.I.H., Extramural 
Research Support, Non-U.S. Gov't 
Review]. Nat Rev Cancer, 9(4), 239-252. doi: 10.1038/nrc2618 
Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial-mesenchymal 
transition. [Research Support, N.I.H., Extramural 
Research Support, Non-U.S. Gov't 
Review]. J Clin Invest, 119(6), 1420-1428. doi: 10.1172/JCI39104 
	  137	  
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordon-Cardo, C., . 
. . Massague, J. (2003). A multigenic program mediating breast cancer 
metastasis to bone. [Comparative Study 
Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, P.H.S.]. Cancer Cell, 3(6), 537-549.  
Kaplan, M. A., Isikdogan, A., Koca, D., Kucukoner, M., Gumusay, O., Yildiz, R., . . . 
Urakci, Z. (2013). Clinical outcomes in patients who received lapatinib plus 
capecitabine combination therapy for HER2-positive breast cancer with brain 
metastasis and a comparison of survival with those who received 
trastuzumab-based therapy: a study by the Anatolian Society of Medical 
Oncology. Breast Cancer. doi: 10.1007/s12282-013-0441-y 
Karasic, T. B., Hei, T. K., & Ivanov, V. N. (2010). Disruption of IGF-1R signaling 
increases TRAIL-induced apoptosis: a new potential therapy for the 
treatment of melanoma. [Research Support, N.I.H., Extramural]. Exp Cell 
Res, 316(12), 1994-2007. doi: 10.1016/j.yexcr.2010.04.014 
Kato, H., Faria, T. N., Stannard, B., Roberts, C. T., Jr., & LeRoith, D. (1994). 
Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like 
growth factor-I (IGF-I) receptor in IGF-I action. [Research Support, Non-U.S. 
Gov't]. Mol Endocrinol, 8(1), 40-50.  
Kim, J., Villadsen, R., Sorlie, T., Fogh, L., Gronlund, S. Z., Fridriksdottir, A. J., . . . 
Petersen, O. W. (2012). Tumor initiating but differentiated luminal-like breast 
	  138	  
cancer cells are highly invasive in the absence of basal-like activity. 
[Research Support, N.I.H., Extramural 
Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, Non-P.H.S.]. Proc Natl Acad Sci U S A, 109(16), 
6124-6129. doi: 10.1073/pnas.1203203109 
Krutzik, P. O., & Nolan, G. P. (2003). Intracellular phospho-protein staining 
techniques for flow cytometry: monitoring single cell signaling events. 
[Comparative Study 
Research Support, U.S. Gov't, P.H.S.]. Cytometry A, 55(2), 61-70. doi: 
10.1002/cyto.a.10072 
Langley, R. R., & Fidler, I. J. (2011). The seed and soil hypothesis revisited--the role 
of tumor-stroma interactions in metastasis to different organs. [Research 
Support, N.I.H., Extramural 
Review]. Int J Cancer, 128(11), 2527-2535. doi: 10.1002/ijc.26031 
Lavoie, J. N., L'Allemain, G., Brunet, A., Muller, R., & Pouyssegur, J. (1996). Cyclin 
D1 expression is regulated positively by the p42/p44MAPK and negatively by 
the p38/HOGMAPK pathway. [Research Support, Non-U.S. Gov't]. J Biol 
Chem, 271(34), 20608-20616.  
Law, J. H., Habibi, G., Hu, K., Masoudi, H., Wang, M. Y., Stratford, A. L., . . . Dunn, 
S. E. (2008). Phosphorylated insulin-like growth factor-i/insulin receptor is 
	  139	  
present in all breast cancer subtypes and is related to poor survival. 
[Research Support, Non-U.S. Gov't]. Cancer Res, 68(24), 10238-10246. doi: 
10.1158/0008-5472.CAN-08-2755 
Ledford, H. (2011). Cancer theory faces doubts. [News]. Nature, 472(7343), 273. 
doi: 10.1038/472273a 
Lee, B. C., Lee, T. H., Avraham, S., & Avraham, H. K. (2004). Involvement of the 
chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha 
in breast cancer cell migration through human brain microvascular 
endothelial cells. [Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, P.H.S.]. Mol Cancer Res, 2(6), 327-338.  
Lee, S. S., Ahn, J. H., Kim, M. K., Sym, S. J., Gong, G., Ahn, S. D., . . . Kim, W. K. 
(2008). Brain metastases in breast cancer: prognostic factors and 
management. Breast Cancer Res Treat, 111(3), 523-530. doi: 
10.1007/s10549-007-9806-2 
Lin, N. U., & Winer, E. P. (2007). Brain metastases: the HER2 paradigm. [Research 
Support, Non-U.S. Gov't 
Review]. Clin Cancer Res, 13(6), 1648-1655. doi: 10.1158/1078-0432.CCR-06-2478 
Lin, Q., Balasubramanian, K., Fan, D., Kim, S. J., Guo, L., Wang, H., . . . Fidler, I. J. 
(2010). Reactive astrocytes protect melanoma cells from chemotherapy by 
	  140	  
sequestering intracellular calcium through gap junction communication 
channels. [Research Support, N.I.H., Extramural 
Research Support, Non-U.S. Gov't]. Neoplasia, 12(9), 748-754.  
Litzenburger, B. C., Creighton, C. J., Tsimelzon, A., Chan, B. T., Hilsenbeck, S. G., 
Wang, T., . . . Lee, A. V. (2011). High IGF-IR activity in triple-negative breast 
cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR 
therapy. [Research Support, N.I.H., Extramural 
Research Support, U.S. Gov't, Non-P.H.S.]. Clin Cancer Res, 17(8), 2314-2327. 
doi: 10.1158/1078-0432.CCR-10-1903 
Lockman, P. R., Mittapalli, R. K., Taskar, K. S., Rudraraju, V., Gril, B., Bohn, K. A., . 
. . Smith, Q. R. (2010). Heterogeneous blood-tumor barrier permeability 
determines drug efficacy in experimental brain metastases of breast cancer. 
[Research Support, N.I.H., Extramural 
Research Support, N.I.H., Intramural 
Research Support, U.S. Gov't, Non-P.H.S.]. Clin Cancer Res, 16(23), 5664-5678. 
doi: 10.1158/1078-0432.CCR-10-1564 
Lopez, T., & Hanahan, D. (2002). Elevated levels of IGF-1 receptor convey invasive 
and metastatic capability in a mouse model of pancreatic islet tumorigenesis. 
[Research Support, U.S. Gov't, P.H.S.]. Cancer Cell, 1(4), 339-353.  
	  141	  
Lorger, M., Lee, H., Forsyth, J. S., & Felding-Habermann, B. (2011). Comparison of 
in vitro and in vivo approaches to studying brain colonization by breast 
cancer cells. [Comparative Study 
In Vitro 
Research Support, N.I.H., Extramural 
Research Support, Non-U.S. Gov't]. J Neurooncol, 104(3), 689-696. doi: 
10.1007/s11060-011-0550-4 
Luga, V., Zhang, L., Viloria-Petit, A. M., Ogunjimi, A. A., Inanlou, M. R., Chiu, E., . . . 
Wrana, J. L. (2012). Exosomes mediate stromal mobilization of autocrine 
Wnt-PCP signaling in breast cancer cell migration. [Research Support, Non-
U.S. Gov't]. Cell, 151(7), 1542-1556. doi: 10.1016/j.cell.2012.11.024 
Maor, S. B., Abramovitch, S., Erdos, M. R., Brody, L. C., & Werner, H. (2000). 
BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: 
potential interaction between BRCA1 and Sp1. [Research Support, Non-U.S. 
Gov't]. Mol Genet Metab, 69(2), 130-136. doi: 10.1006/mgme.1999.2958 
Mardilovich, K., Pankratz, S. L., & Shaw, L. M. (2009). Expression and function of 
the insulin receptor substrate proteins in cancer. Cell Commun Signal, 7, 14. 
doi: 10.1186/1478-811X-7-14 
	  142	  
Martin, J. L., & Baxter, R. C. (2011). Signalling pathways of insulin-like growth 
factors (IGFs) and IGF binding protein-3. [Review]. Growth Factors, 29(6), 
235-244. doi: 10.3109/08977194.2011.614237 
Martin, J. L., Lin, M. Z., McGowan, E. M., & Baxter, R. C. (2009). Potentiation of 
growth factor signaling by insulin-like growth factor-binding protein-3 in 
breast epithelial cells requires sphingosine kinase activity. [Research 
Support, Non-U.S. Gov't]. J Biol Chem, 284(38), 25542-25552. doi: 
10.1074/jbc.M109.007120 
McCaig, C., Perks, C. M., & Holly, J. M. (2002). Intrinsic actions of IGFBP-3 and 
IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation 
of attachment and survival is dependent upon the presence of fibronectin. 
[Research Support, Non-U.S. Gov't]. J Cell Sci, 115(Pt 22), 4293-4303.  
Mehta, A. I., Brufsky, A. M., & Sampson, J. H. (2012). Therapeutic approaches for 
HER2-positive brain metastases: Circumventing the blood-brain barrier. 
Cancer Treat Rev. doi: 10.1016/j.ctrv.2012.05.006 
Menu, E., Jernberg-Wiklund, H., Stromberg, T., De Raeve, H., Girnita, L., Larsson, 
O., . . . Vanderkerken, K. (2006). Inhibiting the IGF-1 receptor tyrosine kinase 
with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse 
model. [Comparative Study 
In Vitro 
	  143	  
Research Support, Non-U.S. Gov't]. Blood, 107(2), 655-660. doi: 10.1182/blood-
2005-01-0293 
Nguyen, D. X., Bos, P. D., & Massague, J. (2009). Metastasis: from dissemination 
to organ-specific colonization. [Research Support, N.I.H., Extramural 
Research Support, Non-U.S. Gov't 
Review]. Nat Rev Cancer, 9(4), 274-284. doi: 10.1038/nrc2622 
O'Han, M. K., Baxter, R. C., & Schedlich, L. J. (2009). Effects of endogenous 
insulin-like growth factor binding protein-3 on cell cycle regulation in breast 
cancer cells. [Research Support, Non-U.S. Gov't]. Growth Factors, 27(6), 
394-408. doi: 10.3109/08977190903185032 
Ocana, O. H., Corcoles, R., Fabra, A., Moreno-Bueno, G., Acloque, H., Vega, S., . . 
. Nieto, M. A. (2012). Metastatic colonization requires the repression of the 
epithelial-mesenchymal transition inducer Prrx1. [Research Support, Non-
U.S. Gov't]. Cancer Cell, 22(6), 709-724. doi: 10.1016/j.ccr.2012.10.012 
Ohlsson, C., Kley, N., Werner, H., & LeRoith, D. (1998). p53 regulates insulin-like 
growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine 
phosphorylation in an osteosarcoma cell line: interaction between p53 and 
Sp1. Endocrinology, 139(3), 1101-1107.  
Okuda, H., Xing, F., Pandey, P. R., Sharma, S., Watabe, M., Pai, S. K., . . . Watabe, 
K. (2013). miR-7 Suppresses Brain Metastasis of Breast Cancer Stem-Like 
	  144	  
Cells By Modulating KLF4. Cancer Res. doi: 10.1158/0008-5472.CAN-12-
2037 
Padovani, L., Muracciole, X., & Regis, J. (2012). gamma knife radiosurgery of brain 
metastasis from breast cancer. [Review]. Prog Neurol Surg, 25, 156-162. doi: 
10.1159/000331189 
Paget, S. (1989). The distribution of secondary growths in cancer of the breast. 
1889. [Biography 
Classical Article 
Historical Article]. Cancer Metastasis Rev, 8(2), 98-101.  
Paharkova-Vatchkova, V., & Lee, K. W. (2010). Nuclear export and mitochondrial 
and endoplasmic reticulum localization of IGF-binding protein 3 regulate its 
apoptotic properties. [Research Support, N.I.H., Extramural 
Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, Non-P.H.S.]. Endocr Relat Cancer, 17(2), 293-302. 
doi: 10.1677/ERC-09-0106 
Palmieri, D., Bronder, J. L., Herring, J. M., Yoneda, T., Weil, R. J., Stark, A. M., . . . 
Steeg, P. S. (2007). Her-2 overexpression increases the metastatic 
outgrowth of breast cancer cells in the brain. [Research Support, Non-U.S. 
Gov't]. Cancer Res, 67(9), 4190-4198. doi: 10.1158/0008-5472.CAN-06-3316 
	  145	  
Park, E. J., Zhang, Y. Z., Vykhodtseva, N., & McDannold, N. (2012). Ultrasound-
mediated blood-brain/blood-tumor barrier disruption improves outcomes with 
trastuzumab in a breast cancer brain metastasis model. [Research Support, 
N.I.H., Extramural 
Research Support, Non-U.S. Gov't]. J Control Release, 163(3), 277-284. doi: 
10.1016/j.jconrel.2012.09.007 
Peng, L., Malloy, P. J., & Feldman, D. (2004). Identification of a functional vitamin D 
response element in the human insulin-like growth factor binding protein-3 
promoter. [Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, Non-P.H.S. 
Research Support, U.S. Gov't, P.H.S.]. Mol Endocrinol, 18(5), 1109-1119. doi: 
10.1210/me.2003-0344 
Pennisi, P. A., Barr, V., Nunez, N. P., Stannard, B., & Le Roith, D. (2002). Reduced 
expression of insulin-like growth factor I receptors in MCF-7 breast cancer 
cells leads to a more metastatic phenotype. Cancer Res, 62(22), 6529-6537.  
Quigley, M. R., Fukui, O., Chew, B., Bhatia, S., & Karlovits, S. (2012). The shifting 
landscape of metastatic breast cancer to the CNS. Neurosurg Rev. doi: 
10.1007/s10143-012-0446-6 
	  146	  
Rodon, J., DeSantos, V., Ferry, R. J., Jr., & Kurzrock, R. (2008). Early drug 
development of inhibitors of the insulin-like growth factor-I receptor pathway: 
lessons from the first clinical trials. [Research Support, Non-U.S. Gov't 
Review]. Mol Cancer Ther, 7(9), 2575-2588. doi: 10.1158/1535-7163.MCT-08-0265 
Rodriguez, L. G., Wu, X., & Guan, J. L. (2005). Wound-healing assay. [Research 
Support, U.S. Gov't, P.H.S.]. Methods Mol Biol, 294, 23-29.  
Sacanna, E., Ibrahim, T., Gaudio, M., Mercatali, L., Scarpi, E., Zoli, W., . . . 
Amadori, D. (2011). The role of CXCR4 in the prediction of bone metastases 
from breast cancer: a pilot study. Oncology, 80(3-4), 225-231. doi: 
10.1159/000327585 
Sachdev, D., Zhang, X., Matise, I., Gaillard-Kelly, M., & Yee, D. (2010). The type I 
insulin-like growth factor receptor regulates cancer metastasis independently 
of primary tumor growth by promoting invasion and survival. [Research 
Support, N.I.H., Extramural 
Research Support, U.S. Gov't, P.H.S.]. Oncogene, 29(2), 251-262. doi: 
10.1038/onc.2009.316 
Saji, M., Vasko, V., Kada, F., Allbritton, E. H., Burman, K. D., & Ringel, M. D. 
(2005). Akt1 contains a functional leucine-rich nuclear export sequence. 
[Research Support, Non-U.S. Gov't]. Biochem Biophys Res Commun, 
332(1), 167-173. doi: 10.1016/j.bbrc.2005.04.109 
	  147	  
Saunus, J. M., Momeny, M., Simpson, P. T., Lakhani, S. R., & Da Silva, L. (2011). 
Molecular aspects of breast cancer metastasis to the brain. Genet Res Int, 
2011, 219189. doi: 10.4061/2011/219189 
Schedlich, L. J., & Graham, L. D. (2002). Role of insulin-like growth factor binding 
protein-3 in breast cancer cell growth. [Research Support, Non-U.S. Gov't 
Review]. Microsc Res Tech, 59(1), 12-22. doi: 10.1002/jemt.10173 
Scheel, C., Onder, T., Karnoub, A., & Weinberg, R. A. (2007). Adaptation versus 
selection: the origins of metastatic behavior. [Research Support, N.I.H., 
Extramural 
Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, Non-P.H.S. 
Review]. Cancer Res, 67(24), 11476-11479; discussion 11479-11480. doi: 
10.1158/0008-5472.CAN-07-1653 
Shaw, L. M. (2011). The insulin receptor substrate (IRS) proteins: at the intersection 
of metabolism and cancer. [Research Support, N.I.H., Extramural 
Research Support, Non-U.S. Gov't 
Review]. Cell Cycle, 10(11), 1750-1756.  
	  148	  
Shiraishi, I., Melendez, J., Ahn, Y., Skavdahl, M., Murphy, E., Welch, S., . . . 
Sussman, M. A. (2004). Nuclear targeting of Akt enhances kinase activity 
and survival of cardiomyocytes. [Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, P.H.S.]. Circ Res, 94(7), 884-891. doi: 
10.1161/01.RES.0000124394.01180.BE 
Sierra, A., Price, J. E., Garcia-Ramirez, M., Mendez, O., Lopez, L., & Fabra, A. 
(1997). Astrocyte-derived cytokines contribute to the metastatic brain 
specificity of breast cancer cells. [Research Support, Non-U.S. Gov't]. Lab 
Invest, 77(4), 357-368.  
Sivaprasad, U., Fleming, J., Verma, P. S., Hogan, K. A., Desury, G., & Cohick, W. 
S. (2004). Stimulation of insulin-like growth factor (IGF) binding protein-3 
synthesis by IGF-I and transforming growth factor-alpha is mediated by both 
phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways 
in mammary epithelial cells. [Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, Non-P.H.S.]. Endocrinology, 145(9), 4213-4221. doi: 
10.1210/en.2003-1377 
Sperduto, P. W., Chao, S. T., Sneed, P. K., Luo, X., Suh, J., Roberge, D., . . . 
Mehta, M. (2010). Diagnosis-specific prognostic factors, indexes, and 
treatment outcomes for patients with newly diagnosed brain metastases: a 
multi-institutional analysis of 4,259 patients. [Multicenter Study]. Int J Radiat 
Oncol Biol Phys, 77(3), 655-661. doi: 10.1016/j.ijrobp.2009.08.025 
	  149	  
Stahl, J. M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M. 
W., . . . Robertson, G. P. (2004). Deregulated Akt3 activity promotes 
development of malignant melanoma. [Research Support, Non-U.S. Gov't]. 
Cancer Res, 64(19), 7002-7010. doi: 10.1158/0008-5472.CAN-04-1399 
Steeg, P. S., Camphausen, K. A., & Smith, Q. R. (2011). Brain metastases as 
preventive and therapeutic targets. [Research Support, N.I.H., Intramural 
Research Support, U.S. Gov't, Non-P.H.S. 
Review]. Nat Rev Cancer, 11(5), 352-363. doi: 10.1038/nrc3053 
Stromberg, T., Ekman, S., Girnita, L., Dimberg, L. Y., Larsson, O., Axelson, M., . . . 
Jernberg-Wiklund, H. (2006). IGF-1 receptor tyrosine kinase inhibition by the 
cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple 
myeloma cells. [Research Support, Non-U.S. Gov't]. Blood, 107(2), 669-678. 
doi: 10.1182/blood-2005-01-0306 
Su, X., Chakravarti, D., Cho, M. S., Liu, L., Gi, Y. J., Lin, Y. L., . . . Flores, E. R. 
(2010). TAp63 suppresses metastasis through coordinate regulation of Dicer 
and miRNAs. [Research Support, N.I.H., Extramural 
Research Support, Non-U.S. Gov't]. Nature, 467(7318), 986-990. doi: 
10.1038/nature09459 
	  150	  
Takata, Y., & Kobayashi, M. (1994). Insulin-like growth factor I signalling through 
heterodimers of insulin and insulin-like growth factor I receptors. [Research 
Support, Non-U.S. Gov't]. Diabete Metab, 20(1), 31-36.  
Taniguchi, C. M., Ueki, K., & Kahn, R. (2005). Complementary roles of IRS-1 and 
IRS-2 in the hepatic regulation of metabolism. [Research Support, N.I.H., 
Extramural 
Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, P.H.S.]. J Clin Invest, 115(3), 718-727. doi: 
10.1172/JCI23187 
Tanno, S., Tanno, S., Mitsuuchi, Y., Altomare, D. A., Xiao, G. H., & Testa, J. R. 
(2001). AKT activation up-regulates insulin-like growth factor I receptor 
expression and promotes invasiveness of human pancreatic cancer cells. 
[Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, P.H.S.]. Cancer Res, 61(2), 589-593.  
Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. 
[Review]. Nat Rev Cancer, 2(6), 442-454. doi: 10.1038/nrc822 
Torng, P. L., Lin, C. W., Chan, M. W., Yang, H. W., Huang, S. C., & Lin, C. T. 
(2009). Promoter methylation of IGFBP-3 and p53 expression in ovarian 
endometrioid carcinoma. [Research Support, Non-U.S. Gov't]. Mol Cancer, 8, 
120. doi: 10.1186/1476-4598-8-120 
	  151	  
Tran, M. N., Choi, W., Wszolek, M. F., Navai, N., Lee, I. L., Nitti, G., . . . McConkey, 
D. J. (2013). The p63 protein isoform DeltaNp63alpha inhibits epithelial-
mesenchymal transition in human bladder cancer cells: role of MIR-205. 
[Research Support, N.I.H., Extramural 
Research Support, Non-U.S. Gov't]. J Biol Chem, 288(5), 3275-3288. doi: 
10.1074/jbc.M112.408104 
Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S., & Yang, J. (2012). 
Spatiotemporal regulation of epithelial-mesenchymal transition is essential 
for squamous cell carcinoma metastasis. [Research Support, N.I.H., 
Extramural 
Research Support, Non-U.S. Gov't]. Cancer Cell, 22(6), 725-736. doi: 
10.1016/j.ccr.2012.09.022 
Tsao, M. N., Lloyd, N., Wong, R. K., Chow, E., Rakovitch, E., Laperriere, N., . . . 
Sahgal, A. (2012). Whole brain radiotherapy for the treatment of newly 
diagnosed multiple brain metastases. [Meta-Analysis 
Research Support, Non-U.S. Gov't 
Review]. Cochrane Database Syst Rev, 4, CD003869. doi: 
10.1002/14651858.CD003869.pub3 
Vashisth, H., & Abrams, C. F. (2010). All-atom structural models for complexes of 
insulin-like growth factors IGF1 and IGF2 with their cognate receptor. 
	  152	  
[Research Support, U.S. Gov't, Non-P.H.S.]. J Mol Biol, 400(3), 645-658. doi: 
10.1016/j.jmb.2010.05.025 
Vasilcanu, D., Girnita, A., Girnita, L., Vasilcanu, R., Axelson, M., & Larsson, O. 
(2004). The cyclolignan PPP induces activation loop-specific inhibition of 
tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to 
the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. [Research Support, 
Non-U.S. Gov't]. Oncogene, 23(47), 7854-7862. doi: 10.1038/sj.onc.1208065 
Vasilcanu, R., Vasilcanu, D., Rosengren, L., Natalishvili, N., Sehat, B., Yin, S., . . . 
Larsson, O. (2008). Picropodophyllin induces downregulation of the insulin-
like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and 
beta-arrestin1. [Research Support, Non-U.S. Gov't]. Oncogene, 27(11), 
1629-1638. doi: 10.1038/sj.onc.1210797 
Vasko, V., Saji, M., Hardy, E., Kruhlak, M., Larin, A., Savchenko, V., . . . Ringel, M. 
D. (2004). Akt activation and localisation correlate with tumour invasion and 
oncogene expression in thyroid cancer. [Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, P.H.S.]. J Med Genet, 41(3), 161-170.  
Vern-Gross, T. Z., Lawrence, J. A., Case, L. D., McMullen, K. P., Bourland, J. D., 
Metheny-Barlow, L. J., . . . Chan, M. D. (2012). Breast cancer subtype affects 
patterns of failure of brain metastases after treatment with stereotactic 
radiosurgery. J Neurooncol, 110(3), 381-388. doi: 10.1007/s11060-012-0976-
3 
	  153	  
Weil, R. J., Palmieri, D. C., Bronder, J. L., Stark, A. M., & Steeg, P. S. (2005). 
Breast cancer metastasis to the central nervous system. [Review]. Am J 
Pathol, 167(4), 913-920. doi: 10.1016/S0002-9440(10)61180-7 
Welsh, J., Wietzke, J. A., Zinser, G. M., Smyczek, S., Romu, S., Tribble, E., . . . 
Narvaez, C. J. (2002). Impact of the Vitamin D3 receptor on growth-
regulatory pathways in mammary gland and breast cancer. [Research 
Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, Non-P.H.S. 
Research Support, U.S. Gov't, P.H.S. 
Review]. J Steroid Biochem Mol Biol, 83(1-5), 85-92.  
Werner, H., Karnieli, E., Rauscher, F. J., & LeRoith, D. (1996). Wild-type and 
mutant p53 differentially regulate transcription of the insulin-like growth factor 
I receptor gene. Proc Natl Acad Sci U S A, 93(16), 8318-8323.  
Werner, H., Re, G. G., Drummond, I. A., Sukhatme, V. P., Rauscher, F. J., 3rd, 
Sens, D. A., . . . Roberts, C. T., Jr. (1993). Increased expression of the 
insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated 
with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene 
product. [Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, P.H.S.]. Proc Natl Acad Sci U S A, 90(12), 5828-
5832.  
	  154	  
Wijnhoven, B. P., Dinjens, W. N., & Pignatelli, M. (2000). E-cadherin-catenin cell-
cell adhesion complex and human cancer. [Research Support, Non-U.S. 
Gov't 
Review]. Br J Surg, 87(8), 992-1005. doi: 10.1046/j.1365-2168.2000.01513.x 
Wilhelm, I., Molnar, J., Fazakas, C., Hasko, J., & Krizbai, I. A. (2013). Role of the 
blood-brain barrier in the formation of brain metastases. Int J Mol Sci, 14(1), 
1383-1411. doi: 10.3390/ijms14011383 
Wu, X., Northcott, P. A., Dubuc, A., Dupuy, A. J., Shih, D. J., Witt, H., . . . Taylor, M. 
D. (2012). Clonal selection drives genetic divergence of metastatic 
medulloblastoma. [Research Support, N.I.H., Extramural 
Research Support, Non-U.S. Gov't]. Nature, 482(7386), 529-533. doi: 
10.1038/nature10825 
Xi, Y., Nakajima, G., Hamil, T., Fodstad, O., Riker, A., & Ju, J. (2006). Association 
of insulin-like growth factor binding protein-3 expression with melanoma 
progression. [Research Support, Non-U.S. Gov't]. Mol Cancer Ther, 5(12), 
3078-3084. doi: 10.1158/1535-7163.MCT-06-0424 
Xia, W., Chen, J. S., Zhou, X., Sun, P. R., Lee, D. F., Liao, Y., . . . Hung, M. C. 
(2004). Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is 
associated with HER2/neu overexpression and provides a novel combination 
predictor for poor prognosis in breast cancer patients. [Research Support, 
	  155	  
U.S. Gov't, P.H.S.]. Clin Cancer Res, 10(11), 3815-3824. doi: 10.1158/1078-
0432.CCR-03-0527 
Yang, H., Lee, H. W., Kim, Y., Lee, Y., Choi, Y. S., Kim, K. H., . . . Nam, D. H. 
(2013). Radiosensitization of brain metastasis by targeting c-MET. Lab 
Invest. doi: 10.1038/labinvest.2012.180 
Yin, S., Girnita, A., Stromberg, T., Khan, Z., Andersson, S., Zheng, H., . . . Girnita, 
L. (2010). Targeting the insulin-like growth factor-1 receptor by 
picropodophyllin as a treatment option for glioblastoma. [Research Support, 
Non-U.S. Gov't]. Neuro Oncol, 12(1), 19-27. doi: 10.1093/neuonc/nop008 
Yoneda, T., Williams, P. J., Hiraga, T., Niewolna, M., & Nishimura, R. (2001). A 
bone-seeking clone exhibits different biological properties from the MDA-MB-
231 parental human breast cancer cells and a brain-seeking clone in vivo 
and in vitro. [Research Support, U.S. Gov't, P.H.S.]. J Bone Miner Res, 
16(8), 1486-1495. doi: 10.1359/jbmr.2001.16.8.1486 
Yoshimine, T., Ushio, Y., Hayakawa, T., Hasegawa, H., Arita, N., Yamada, K., . . . 
Mogami, H. (1985). Immunohistochemical study of metastatic brain tumors 
with astroprotein (GFAP), a glia-specific protein. Tissue architecture and the 
origin of blood vessels. J Neurosurg, 62(3), 414-418. doi: 
10.3171/jns.1985.62.3.0414 
Yu, H., & Rohan, T. (2000). Role of the insulin-like growth factor family in cancer 
development and progression. [Research Support, U.S. Gov't, P.H.S. 
	  156	  
Review]. J Natl Cancer Inst, 92(18), 1472-1489.  
Yuen, J. S., Cockman, M. E., Sullivan, M., Protheroe, A., Turner, G. D., Roberts, I. 
S., . . . Macaulay, V. M. (2007). The VHL tumor suppressor inhibits 
expression of the IGF1R and its loss induces IGF1R upregulation in human 
clear cell renal carcinoma. [Research Support, Non-U.S. Gov't]. Oncogene, 
26(45), 6499-6508. doi: 10.1038/sj.onc.1210474 
Zha, J., & Lackner, M. R. (2010). Targeting the insulin-like growth factor receptor-
1R pathway for cancer therapy. Clin Cancer Res, 16(9), 2512-2517. doi: 
10.1158/1078-0432.CCR-09-2232 
 
	  157	  
VITA 
Sandra Maria Saldaña Sanchez was born in Monterrey, Nuevo Leon, Mexico on 
August 9th, 1984.  She is the daughter of Orlando Saldaña and Maria J. Saldaña, 
and the older sister of Orlando Saldaña.  She moved to Houston, Texas, along with 
her parents and younger brother when she was 12 years old.  She received a 
Bachelor of Arts in biological sciences, with a minor in microbiology, from the 
College of Arts and Sciences at Cornell University in 2006.  At Cornell, Sandra was 
an undergraduate research scholar under the Cornell Nanobiotechnology Center.  
In the Fall of 2006, she enrolled in the PhD program at the UT Health Science 
Center at Houston Graduate School of Biomedical Sciences and joined the 
Department of Molecular and Cellular Oncology at the University of Texas MD 
Anderson Cancer Center.  She will complete her Doctorate of Philosophy in Cancer 
Biology in May of 2013. 
 
 
 
 
 
Copyright (c) 2013 Sandra Maria Saldaña 
All rights reserved 
